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ABSTRACT
Numerous studies have shown that cells and tissues grown in 2D substrates behave
dramatically differently than in the body, and that culturing them in three dimen-
sional (3D) scaffolds can restore some of this lost functionality. 3D scaffolds can
provide structural support to an injury site in the body, aiding the growth of healthy
tissue. Outside of the body, scaffolds can be used to test pharmaceuticals, collecting
data in an environment that represents the body better than traditional 2D cultures.
This could potentially save millions of dollars in drug development costs.
For these reasons, this dissertation focuses on the utilization of inverted colloidal
crystal (ICC) scaffolds for bone and bone marrow engineering. ICC scaffolds are ma-
trices that have a highly ordered 3D structure of interconnected spherical cavities.
This dissertation describes the first ICC scaffold composed of a biodegradable poly-
mer, poly(lactic-co-glycolic acid) (PLGA). Within these scaffolds, the scaffold cavity
sizes were controlled on the micro-scale by utilizing different beads sizes, 100, 200, and
330 µm, as the scaffold template. Additionally, the size of the channels that connect
the cavities were controlled within the range of 660-710 ◦C by changing the annealing
temperature. The compressive moduli of these scaffolds were in the range of 55-63
MPa. Lastly, biocompatibility with a human osteoblast cell line was demonstrated.
Next, the dissertation utilized polyacrylamide hydrogel ICC scaffolds to engineer a
human hematopoietic stem cell (HSC) niche. ICC scaffolds demonstrated significantly
greater HSC expansion than 2D cultures. This work was continued by comparing the
ICC scaffolds to Matrigel and 2D cultures. Here, it was observed that ICC cultures
xv
demonstrated stable numbers of HSCs throughout 14 days. 2D cultures expanded
the number of HSCs 6-8× over 14 days and Matrigel cultures expanded differentiated
cells but few HSCs. These results indicated that physical cell-cell interactions cause
quiescence or preservation of the HSC phenotype, and the absence of direct cell-cell
interactions causes HSC differentiation. Lastly, preliminary data was collected in




1.1 Introduction to 3D cell culture
The human body is a complex system of organs and tissues. Within each tissue
lies a dynamic environment of many cell types, extracellular matrix (ECM) molecules,
ions, soluble proteins, and other soluble signaling molecules. For years, scientists have
grown cells in vitro, cultures outside of the body, to learn about the functions and
interactions between the different cell types. These early cultures were composed of
cells growing on two dimensional (2D) surfaces, such as petri dishes, and brought
forth a great many discoveries about cellular biology [1] and how to manipulate them
to yield commercial products, such as the polio vaccine [2]. An important use for 2D
cell cultures has been the testing of efficacy and toxicity of pharmaceuticals.
Despite the many advances that came from 2D cell cultures, cells lose a great
deal of functionality when they are grown on flat surfaces. Fig 1.1 demonstrates the
obvious differences between cells grown on 2D surfaces and those in the body. For
example, bone is composed mainly of ECM, primarily type I collagen and hydroxyap-
atite, with cells dispersed through the matrix. On the surface of bone, osteoblasts lie
in sheets in a cuboidal configuration (Fig 1.1A). In vitro, cells lie flat on 2D surfaces
(Fig 1.1B). Likewise, hepatocytes, the basic cell type of the liver, form hexagonal
lobules separated by connective tissue in the body (Fig 1.1D) [3], but lie flat in 2D
(Fig 1.1E). In the thymus, lymphocytes exist in suspension (Fig 1.1G) but lie unnat-
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urally when cultured on in 2D (Fig 1.1H).
Many of the architectural and functional aspects of these cell types are regained
when they are cultured in a more complex microenvironment. When grown in 3D
matrices, also called scaffolds, the cell types in Fig 1.1 regain some of the morphology
and function that is seen in vivo (Figs. 1.1C, F, and I). T cells [4], breast epithelial
cells [5], and ovarian follicles [6] have been shown to regain functionalities in 3D
matrices. For these reasons, the applications of 3D cell culture have expanded since
its first conception 30 years ago [7].
1.2 Applications of 3D cell cultures
In the most basic sense, scaffolds are 3D porous structures that can support cell
attachment and growth. With further engineering, some scaffolds have been tailored
to cause cellular organization or differentiation [13–17]. The ultimate goal of utilizing
3D scaffolds for cell culture is to engineer tissues or tissue-like models for either
implantation into the body to aid recovery of damaged tissues or to study cells or
tissues ex vivo.
Tissue engineering, one of the most prominent applications for 3D cell culture,
aims to replace or aid the healing of damaged or diseased tissues in the body [18].
One approach to tissue engineering is to utilize a 3D matrix to grow tissues in vitro
that can be used as an off-the-shelf supply to implant into patients. For example, a
readily available supply of skin could be used to save victims with severe burns [19].
Another approach aims to insert the matrix in the body, possibly in combination
with cells and/or signals, to support the wound site as body tissue grows into the
implant. Such an approach is especially progressed in the areas of bone and cartilage
engineering [20–22]. In each case, the matrix would theoretically degrade so that only
new healthy tissue remains.
3D cultures can also be used to increase basic understanding of the body. Here,
2
Figure 1.1: Organization of natural tissue, 2D cell cultures, and 3D cell cultures [8].
(A, D) Histological images of (A) bone and (D) liver [3]. (G) Scanning
electron microscope image of the thymus [9]. (B, E, H) Optical micro-
scope images of cells grown on 2D substrates. (B) osteoblasts, (E) hepa-
tocytes, and (H) co-culture of lymphocytes and stromal cells [9]. Cellular
morphology becomes closer to that of natural tissue when cultured on
3D matrices; different appearance of (C) osteoblasts [10] (F) hepatocytes
[11], and (I) mononuclear cells in a 3D matrix [12].
one could isolate one or several cells from the body and study cell-cell or cell-matrix
interactions in the scaffold. For example, engineered 3D tumor models gave light to
the growth factors that may be involved in the development of new blood vessels in
tumors [23]. Similar 3D tumor models have elucidated enzymes that facilitate cancer
growth [24].
The last application to be considered is the use of in vitro cells and tissues for
pharmaceutical drug testing. A major problem with the current drug development
3
paradigm is that potential drugs are not introduced into humans until late in the
testing process. Cells growing in 2D are an oversimplified model of the body, and
animal testing is not always accurate. As a result, it is not known whether a drug will
be effective until after 10 years and millions of dollars of investment. It is possible
that an ex vivo 3D model in which cells are behaving more like the human body
would be a predictive tool for drug testing, lessening the time and money spent on
development. Here, cells or tissues would be cultured in a 3D matrix so that their
behavior mimics that of tissues in the human body. Cultured in a well-plate format,
healthy or diseased model tissues could be used in a high-throughput environment to
predict how the body will react to the drug.
1.3 Introduction to ICC scaffolds
The studies in this dissertation focus on the use of ICC scaffolds for bone and bone
marrow engineering. ICCs were developed by the Kotov group as 3D matrices with
precise feature size control [8, 25–29]. The ICC manufacturing process is depicted
in Fig 1.2. First, a template of tightly-packed array of uniformly-sized microspheres,
called a colloidal crystal (CC), is created by slow deposition of beads into a mold under
agitation. Next, the microspheres are heated above their glass transition temperature
so that the beads slightly connect to one another, forming a solid structure. A liquid
polymer solution is then infiltrated into the template and the polymer is solidified,
either by evaporating solvent (organic-soluble polymers) or crosslinking (hydrogels).
Lastly, the bead template is dissolved, leaving behind an ICC. In this structure, the
cavities exist where the microspheres had been, interconnected by channels where the
beads were annealed together.
ICC scaffolds have been used in a variety of applications. The first ICC scaffolds
were composed of silicate, and were shown to support the growth of hepatocytes
and bone marrow stromal cells [26, 28]. Next, the scaffolds were fabricated utilizing
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Figure 1.2: Schematic of ICC fabrication process. (A) CCs are produced by sedi-
menting uniformly-sized microspheres into an ordered array. Next, the
microspheres are annealed and the space around the spheres is infiltrated
with a liquid solution of the scaffold material. Last, the beads are dis-
solved, leaving an ordered array of cavities with connections where the
beads had touched. (B) SEM image of ICC scaffold and ordered micro-
sphere template (inset).
polyacrylamide hydrogel [27, 29]. The polyacrylamide in these studies held a neutral
surface charge and did not facilitate cell attachment. As a result, the scaffolds were
coated with Layer-by-layer (LBL) applied films to make possible cell attachment for
the cell types mentioned above, as well as HSCs [12, 30] (Fig 1.3A). The neutral
properties of polyacrylamide were taken advantage of in ICC scaffolds to grow hepa-
tocyte spheroids (Fig 3B) [8, 31]. The cells assembled into spheroids within the ICC
cavities because the cell-cell attractions were stronger than cell-scaffold attractions
(Fig 1.3B). Most recently, a cationic polyacrylamide was developed to facilitate cell
attachment without LBL surface coatings [32]. In addition to the various hydrogel
scaffolds mentioned above, ICC scaffolds were fabricated utilizing a biodegradable
polymer for bone tissue engineering that facilitated the attachment of osteoblasts
[25].
ICC scaffolds, particularly those that are made of hydrogel, have several major
advantages over other matrices. First, the high degree of order yields little scaffold-to-
scaffold variation, allowing for more reliable data collection. The matrix is transpar-
ent, so that the user can view live cells directly in the scaffold via confocal microscopy.
Last, hydrogel matrix is not reorganized by the cells so, unlike ECM-based matrices,
the structure does not change or disappear throughout the culture.
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Figure 1.3: Cell cultures in ICC scaffolds. (A) SEM image of HSCs (yellow) cultured
with stromal cells (red) in acrylamide ICC scaffolds with an LBL surface
coating [12]. (B) Confocal microscopy image of hepatocyte spheroids (red)
in acrylamide ICC scaffolds without LBL coating [17].
1.4 ICC scaffolds for bone and bone marrow engineering
The focus of this dissertation is on the engineering of bone and bone marrow.
These tissues have essential and complex cell-cell and cell-matrix interactions that
are lost in 2D cultures. The application of ICC scaffolds to these tissues is obvious
due to the architectural similarity of trabecular bone and ICCs (Fig 1.4). The ability
to control the size of architecture features affords the potential for high mechanical
properties, which is important when designing an implant for a structural tissue like
bone. Within bone, bone marrow is home to intense interactions between HSCs,
stromal cells, and the surrounding bone and ECM; these intense interactions can be
mimicked utilizing the geometry of ICC scaffolds.
1.5 Organization of the dissertation
This chapter introduced the principles and applications of 3D cell culture. Chap-
ter 2 will review scaffold manufacturing processes, some relevant materials, and close
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Figure 1.4: Geometrical similarities between trabecular bone and ICC scaffolds. SEM
images of (A) trabecular bone and (B) ICC scaffolds [25].
with relevant work in bone tissue engineering, bone marrow engineering and pharma-
ceutical drug testing in bone marrow. The next chapter discusses the development
of biodegradable ICC scaffolds for applications in bone tissue engineering. Chapter
4 presents work on the use of hydrogel ICC scaffolds for bone marrow engineering.
Chapter 5 compares three matrices and combinations of stromal cells for bone tissue
engineering. The next chapter continues with the use of ICC scaffolds as bone mar-
row analogs and preliminary drug testing. The final chapter summarizes the work
presented in the dissertation and discusses future work.
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CHAPTER II
Literature Review and Background
This dissertation focuses on the engineering of bone and bone marrow from two
design perspectives: (1) implantable matrices for bone tissue engineering and (2)
in vitro models of bone marrow for drug testing. These applications have different
design criteria for 3D matrices. Tissue engineering targets the creation of functional
implants using artificial 3D matrices [18, 33]. Scaffolds are designed to be implanted
in a patient wound site to act as a temporary template to restore original tissue
function while the natural tissue heals. Accordingly, scaffolds should not only have
proper architecture for supporting cell growth, but should also match the shape of the
defect site. Materials should be biodegradable and metabolized in the body without
causing serious systemic or immunogenic problems [34]. In vitro modeling, however,
aims to utilize the cell-matrix complex as a tool to improve the understanding of
tissue physiology and pathophysiology [35]. The user may want the matrix to be
inert so that its shape and organization does not change with time. The 3D matrix
should be designed to mimic the organization and function of tissues in the body;
thus, geometrical and material property control is extremely important. It is also
essential that the matrix is optically accessible to analyze tissue growth and function
within the scaffold.
With these applications in mind, this chapter will focus on the different structural
design criteria and fabrication methods for 3D matrices. It will also briefly discuss
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categories of materials used in 3D matrices relevant to these topics. More detailed
information about materials, as well as other considerations and examples of using
3D matrices can be found in a review paper by Lee et al [8]. Lastly, this chapter will
summarize relevant work performed in the areas of bone tissue engineering and 3D
models of bone marrow.
2.1 Geometrical properties of scaffolds
With a growing variety of available techniques to control the size and shape of
materials from the nano- to the micro-scales, scaffold design has become increas-
ingly precise. A multi-scale approach to 3D matrix design is especially important in
mimicking living systems, as nature often derives properties from multi-scale or hier-
archical design, which previously have been difficult to mimic. For example, much of
the toughness of bone originates in the hierarchical structure of interacting nano-scale
collagen molecules and hydroxyapatite crystals, collagen fibers and fibrils, micro-scale
lamella and osteons [36]. Multiple levels of control allow for the engineering of unique
scaffold properties not present in bulk materials, including geometry, porosity, surface
texture, cell seeding, signal delivery, and many other matrix characteristics.
2.1.1 Macro-scale
The macro-scale structure, which is defined here to be on the scale of 100 - 10-3
m, mainly is engineered to tailor the size and shape of the scaffold (Fig. 2.1A, B). For
in-vitro 3D cell culture applications, the size and shape of a matrix can be controlled
for convenience and functionality (e.g., fitting to a well plate or bioreactor). In
the simplest case, scaffolds can be fabricated directly in a cylindrical mold, such
as a vial with the desired diameter. In tissue engineering, it is important to match
matrix size and shape to the anatomical defect. For example, a scaffold for bone
tissue engineering should have a properly designed macro-scale structure to allow for
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integration with adjacent tissues, as well as to generate properly sized tissue [37, 38].
A major challenge is that defect site size and shape vary from patient to patient. One
approach to achieving this level of design control is to use computer-based medical
imaging tools such as computed tomography and magnetic resonance imaging and
design strategies such as computer-aided design, which become useful in customizing
the 3D architecture to match a wound site [38]. This design can be manufactured
using solid free-form (SFF) fabrication, which will be discussed further in Section
2.1.2. The macroscopic structural design of 3D matrices, along with their fast and
individualized production, will become more important with the realization of 3D cell
scaffolds in clinical applications [39–41].
Figure 2.1: Multiple scales of design criteria of 3D cell culture matrices. (A) [38]. (B)
[42]. (C) [43]. (D) [44]. (E) [45]. (F) [46]. (G) [44]. (H) [47].
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2.1.2 Micro-scale design
Features of interest that are affected by micro-scale (10-310-6 m) structure include
porosity, pore interconnectivity, pore geometry, pore size distribution, mechanical
properties, and topography. These features directly affect the diffusion of nutrients,
metabolic wastes, and other soluble molecules. The inclusion of sufficiently sized and
well-interconnected pores improves diffusion throughout the scaffold interior. Pore
geometry is also a great influence on the scaffold diffusion properties, as different
pore shapes can yield different mass transport profiles (Fig. 2.1C, D). As well, a large
pore size distribution can lead to areas with poorer accessibility, potentially limiting
cell seeding and migration efficiency. The porosity can also affect the mechanical
properties of the scaffold. A highly porous scaffold can lose mechanical strength
due to the lack of material. Lastly, micro-scale features also are of note because
cells are of this scale. Individual cells recognize structures that have comparable
dimension to cellular size (10-100 µm) [48]. Micro-scale surface features can activate
certain genes and modulate cellular behavior in differentiation or proliferation. For
example, microscopic surface patterns and grooves on 2D surfaces guide neuronal cell
polarization [48] and myoblast alignment [49].
Traditional scaffold fabrication techniques that impart micro-scale pores include
particulate leaching, gas foaming, emulsion freeze-drying, and thermally induced
phase separation [50–54]. These techniques are based upon bulk material alteration
that yields a random pore structure, leaving the user with little control over the fea-
tures mentioned above. Specifically, a stochastic micro-structural architecture, such
as those resulting from particulate leaching fabrication techniques, yields incomplete
scaffold permeability. Consequently, scaffold porosities often approach 95% to ensure
complete interconnectivity throughout the scaffold [55]. Such high porosities present
a dilemma in bone tissue engineering, where increased porosity enhances intercon-
nectivity but denies the scaffold of sufficient mechanical strength to support the load
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of the body until tissue regeneration is complete. Precise design of matrices, where
architecture is optimized to provide complete interconnectivity at lower porosities,
can improve mechanical strength while preserving effective diffusion [55].
Although there are numerous fabrication methods to make 3D matrices with
micro-scale resolution, some manufacturing methods, such as SFF fabrication [56]
and ICC fabrication [26, 27, 29], provide precise controllability over 3D matrix archi-
tecture at this scale. Computational image-based SFF processes, such as 3D printing,
fused deposition modeling, and selective laser sintering, provide precise control over
scaffold architecture, including interconnectivity and topography, and can be designed
to obtain specific mechanical properties [38]. However, these methods are limited in
useable materials and minimum feature size [55, 57–59]. Still, the larger pore sizes
can provide room for nutrient and waste diffusion, as well as tissue ingrowth when
implanted in vivo and SFF-manufactured scaffolds have possessed mechanical prop-
erties approaching that of hard tissues [38]. Taboas et al. overcame some of the
feature size and material drawbacks of SFF by developing an indirect SFF process
[60]. This process involved casting molds manufactured by direct SFF processes with
a salt-polylactic acid mixture. Leaching the molds and salt created polymeric scaf-
folds with controlled global pores from the SFF molds and local porosity from salt
particles [60]. Recently, methods such as two-proton polymerization have improved
the resolution of SFF techniques to the nano-scale [61]. Continued improvement in
accessible feature sizes will make SFF-based fabrication techniques the most realistic
for commercial tissue engineering purposes.
ICC scaffolds have emerged as a highly organized 3D environment for cell growth
[8, 12, 17, 25–31]. A description of ICC scaffolds and their fabrication is given in
Chapter 1. This arrangement of identical spherical cavities offers a uniform cellular
environment for differentiation and growth, an ideal setting for understanding the
role of cell-cell and cell-scaffold interactions, and for computer modeling of scaffold
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properties [62]. Additionally, the complete interconnectivity at low porosities gave
hydrogel ICC structures a ten to one thousand-fold greater relative stiffness than
those predicted for bulk material alteration techniques in polyethylene glycol hydrogel
scaffolds [63]. ICC structures can be prepared of any bulk material, so long as a
suitable pair of solvents is found: one to dissolve the mold without affecting the
material and vice versa. Ideally, specific design criteria, such as 3D topography
resembling that of trabecular bone, mechanical properties, degradation rate, and
growth factor release rate, can be met by adjusting scaffold material and sphere
size. The ICC structure offers some obvious advantages for bone and bone marrow
engineering such as high degree of structural control, complete interconnectivity of
cavities,and the possibility of achieving high mechanical strength.
2.1.3 Nano-scale design
Nano-scale design, defined as features in the size range of 10-6-10-9 m, is important
to consider when mimicking the human body because cells interact with their environ-
ment via nano-scale ECM proteins and with other cells via nano-scale receptors. For
example, collagen fibrils have a diameter range of 50 to 200 nm, and fibronectin are
60 to 70 nm long and 2 to 3 nm thick. In vitro, nano-scale topological features have
provided significant influence on cellular functions via cell adhesion, organization,
morphology, and differentiation [64].
There are four major methods of imparting nano-sized 3D surface structural fea-
tures onto a 3D matrix. The first method involves using nano-materials such as
3D peptide hydrogels directly, entrapping cells in a 3D nano-scale fibrous structure
(Fig. 2.1E) [45, 65]. The second method incorporates nano-sized materials into bulk
materials before matrix manufacture (Fig. 2.1F) [46]. A great deal of research in
bone tissue engineering has focused on integrating nano-sized features into scaffolds
to improve osteoblast adhesion, proliferation, and calcium deposition. For example,
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hydroxyapatite nano-particles incorporated into the matrix of polylactic acid (PLA)
scaffolds yielded nano-scale topology that significantly increased protein adsorption
[66]. The third method controls processing conditions during fabrication (Fig. 2.1G).
A nano-scale fibrous structure can be produced on the surface of a 3D matrix through
thermally induced phase separation of PLA solution in organic solvent, followed by
a crystallization process during freeze drying [67]. Electrospinning techniques can
also reduce fiber diameter to the nano-scale [68]. The last approach is post- fabri-
cation surface treatment or surface coating (Fig. 2.1H). For example, brief exposure
of 3D polyester scaffolds to sodium hydroxide created nano-scale surface roughness,
which improved the adhesion of osteoblasts and chondrocytes [69]. Although the
above techniques are successful at generating nano-scale surface structures, feature
controllability on 3D structures continues to present a major challenge.
2.1.4 Geometrical scale conclusions
Proper design of 3D cell culture matrix structure on multiple scales can provide
distinct features to the matrix, such as macro-scale shape, micro-scale internal archi-
tecture, and nano-scale surface topology. Therefore, all scales should be considered
when mimicking natural tissue for either tissue engineering or 3D modeling purposes.
The development of processing approaches that allow freedom in choice of macro-,
micro-, and nano-scale is one of the most difficult challenges in 3D scaffolds that the
materials science and nano-technology communities need to address.
2.2 Material considerations for 3D matrices
2.2.1 Criteria for tissue engineering and 3D modeling applications
The materials that are appropriate for the two applications discussed here vary
greatly; however, in both cases the primary consideration is biocompatibility. In
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tissue engineering, the most basic goal is to minimize toxicity such that long-term
immunological responses, such as rejection or fibrous encapsulation, are avoided. Ad-
ditional material considerations include the ability to recruit cells from the natural
tissue into the implant, and degradability into metabolites that occur naturally in the
body. Specifically for bone and other load-bearing tissues, the materials should have
mechanical properties that approach those of healthy tissue. For these reasons, in
tissue engineering, materials are typically synthetic polymers designed to maximize
mechanical properties while undergoing controlled degradation.
The ideal materials of 3D modeling are very different than those of tissue engi-
neering. In this area, the user is growing cells or tissues in a matrix to examine a
certain aspect of the human body; for example, to probe the interactions between
cells, their reaction to a drug, or the effects of the addition or deletion of a gene,
are all uses of ex vivo culture [23, 24, 70]. In these applications, one needs to view
and track cells and markers, requiring that the matrix is transparent. The matrix
should also be inert to its remodelling by cells. For example, biodegradability should
be avoided to evade the effects of material metabolites or change in matrix structure.
2.2.2 Relevant materials
The majority of materials utilized in tissue engineering, specifically in bone tissue
engineering, are synthetic resorbable polymers. Resorbable polymers, which include
poly(α-hydroxyesters), polyanhydrides, and poly(ortho-esters), are useful because
their composition can be tailored to obtain certain properties, including degrada-
tion rate and mechanical properties. As well, their processability allows for a variety
of structural properties such as geometry and porosity.
As 3D modeling requires transparent, nondegradable, materials with properties
much like the body, hydrogels, networks of hydrophilic polymer chains, are com-
monly utilized [71, 72]. Hydrogels are appropriate formats for 3D modeling of many
15
tissues because ECM is a fully hydrated gel [73]. The hydrogel structure also creates
a gradient of soluble signaling molecules within a 3D matrix much like the body,
and absorbs mechanical tensions. Three popular types of synthetic gels are used:
polyethylene glycol (PEG), peptide, and DNA gels. PEG hydrogel has been used be-
cause of its high biocompatibility and precise control of reaction kinetics during rapid
photo-polymerization, providing a spatially well-controlled 3D gel for cell entrapment
[74]. Peptide gels are composed of macroscopically self-assembled synthetic peptides.
Small quantities of elemental peptides (0.1-5.0%) dispersed in water are mixed with
a cell suspension, which then undergoes a self-assembling process under the right
ionic conditions. Self-assembled peptides generate a stable nano-fibrous structure,
entrapping cells. Two types of synthetic peptides currently used in this fashion are
amyloid-like fibrils [75] and peptide amphiphiles [76]. Recently, deoxyribonucleic
acid (DNA) has been used as a building block to construct hydrogels with the in-
vention of an oligonucleotide synthesizer to design a specific sequence of DNA and
polymerase chain reaction to amplify the DNA. Elaborately designed DNA molecules,
which have a branched structure with a complementary sticky end, can be hybridized
to each other via DNA ligase, self-assembling into a 3D DNA hydrogel [77, 78]. Poor
cell adhesion due to the hydrophilicity of hydrogels and the lack of cell binding mo-
tifs is a common drawback [72]. These limitations can be overcome by conjugating
cell-binding motifs such as arginine-glycine-aspartate on polymer chains [79] or by
coating surfaces with bioactive materials post-fabrication [27].
Natural materials tend to show better biocompatibility than synthetic materials,
but their animal sources raise concerns about disease transfection. Natural polymers
include collagen, gelatin, chitosan, alginate, fibrin, Matrigel. Matrigel is protein gel
matrix extracted from Engelbreth-Holm Swarm tumors from mice that has a het-
erogeneous composition of laminin, type IV collagen, heparan sulfate proteoglycan,
entactin, and fibronectin [80, 81]. These soluble proteins undergo self-assembled poly-
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merization when incubated at 37 ◦C, forming a 3D gel [82]. As Matrigel is composed
of matrix from in vivo sources, cells can digest and restructure the matrix [83]. This
feature is useful for migration studies [84], but can be hindering in tissue engineering
applications where matrix digestion disrupt the 3D structure. As well, the murine
source of Matrigel introduces the potential of viral contamination, such as lactate
dehydrogenase-elevating virus.
2.3 Bone Tissue Engineering
The current clinical gold standard in bone replacement is autologous bone, but
lack of availability and donor site morbidity severely limits its applications. Similarly,
allogenic bone grafts are limited by supply and immunogenic response. Therefore,
engineering bone tissue substitutes to regenerate or replace damaged tissue is of great
interest.
The major classes of materials used in bone tissue engineering are metals, ce-
ramics, and polymers. Metals and ceramics, e.g. titanium and calcium phosphate,
respectively, have had some clinical success as bone implants; however, they do not
degrade, which causes loss of strength of natural tissue by shielding local tissue from
mechanical stresses [85, 86]. Furthermore, the materials have their own problems,
such as wear and brittleness. Ideally, scaffolds should be designed to degrade at the
rate that in-growing tissue replaces them. Thus, bone scaffolds generally are com-
posed of syntheitic hydrolytically degradable polymers, which can be tailored to have
certain properties, such as compressive modulus or degradation rate. For example,
the degradation profile of PLGA scaffolds can be manipulated by adjusting the com-
position and molecular weight of PLA and polyglycolic acid (PGA) polymers [87].
Bone possesses a range of mechanical properties superior to most of the men-
tioned synthetic materials (Table 2.1). The organic-inorganic composition of bone is
responsible for the combination of strength and stiffness and high fracture toughness.
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Inorganic hydroxyapatite, in the form of nano-sized platelike crystals, is thought to
contribute to the strength of bone; for example, the Young￿s Modulus of cortical bone
correlates linearly with its mineral content [88]. Collagen, the main organic compo-
nent of bone, is said to contribute to the fracture toughness of bone, the energy
required to cause matrix failure [89]. Other contributors to the mechanical properties
of bone include collagen cross-linking and fibril orientation, mineral crystal size, and
microstructural organization [90].

















PLGA 41.4-55.2 1.4-2.8 [91]
Hydroxyapatite >400 40 100-114 [89, 91]
Noting the nano-scale design of natural bone, engineers have attempted to impart
nano-scale particles and features into scaffolds. Examples of attempts at mimick-
ing the nanocomposite structure of natural bone include mixtures of silica and ap-
atite, calcium phosphate cement microparticles and PLGA, calcium phosphate and
PLGA microparticles, nanostructured titania and PLGA, nano-hydroxyapatite and
PLA, and hydroxyapatite (HA) and chitosan-gelatin [66, 69, 92–95]. Specifically,
there have been several attempts at improving properties of scaffolds by incorporat-
ing HA into polymers. Marra et al. synthesized composite scaffolds with 0-50% HA in
poly(caprolactone), PLGA, and blends of both polymers [96]. The Youngs modulus
was shown only for strips of 10% HA, but this modulus was five times greater than
scaffolds of polymer alone. These results are promising; however, the HA particle
size was not given and results could be significantly improved by incorporating nano-
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sized HA (size not stated) or varying the inorganic-organic ratio. Nano-sized HA was
blended with PLA in ratios of 0-70% HA by Wei et al to obtain 3D structures. A
significant improvement of compressive modulus was seen for 30% and 50% HA com-
pared to polymer alone [66]. Kim et al. created 3D scaffolds with HA nanoparticles
(100 nm length) and 75:25 PLGA in a 1:1 ratio, but the compressive moduli remained
at 2.3-4.5 MPa, most likely due to the 90% porosities obtained from the particulate
leaching method used to produce an interconnecting structure [97].
2.4 Bone Marrow Engineering
The interactions between HSCs and the bone marrow niche are incredibly com-
plex and not completely understood. Bone marrow stroma, the tissue surrounding
hematopoietic tissue, is composed of a variety of cell types and ECM molecules.
Bone cells, such as osteoblasts and osteoclasts, play an important role in HSC main-
tenance through receptor-receptor contact and calcium concentration regulation [98–
101]. HSCs have also been found close to endothelial cells near blood vessels that
enter the marrow [102]. Additional stromal cell types include adipocytes and retic-
ular cells. HSCs interact with these cell types directly through cell-cell contacts, or
indirectly through secreted growth factors or ECM. The ECM of bone marrow stroma
consists of proteins and glycoproteins, such as collagen, osteopontin, and fibronectin
[103, 104].
Models of the HSC niche and of bone marrow are desirable for expansion of HSCs
and also for testing of drugs within the tissue. Despite the complexity of bone marrow,
most models of healthy and diseased HSCs and marrow consist of one or two cell
types growing on 2D surfaces. Furthermore, most HSC engineering focuses on their
expansion [105–108] and little has been explored in controlled development of HSCs
into whole bone marrow.
Traditionally, models of the HSC niche were grown on 2D surfaces, either on
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stromal cells [109, 110], supplemented with high concentrations of growth factors
[111, 112], or both. The 2D models allowed for the maintenance and expansion of
HSC, but lack the dimensionality and ECM components of the HSC niche. With
this in mind, 3D models of the bone marrow niche, primarily designed for HSC ex-
pansion, were developed. These models ranged from nanofiber scaffolds [105, 108] to
porous natural polymers [113] and synthetic polymers [114, 115]. Due to the pres-
ence of nanoscale ECM fibers, structures with nanoscale features have been incorpo-
rated into 3D matrices for the culture of HSCs; these include electrospun nanofibers
[105, 108], nanoridges [4], and nanocomposites [30, 116]. One of the most commonly
used nanostructured matrices used in hematopoietic and other stem cell cultures is a
commercially available matrix called Matrigel [117, 118].
Most applications of 3D matrices to bone marrow niches are relatively recent.
Given the complex cell-cell and cell-matrix interactions in bone marrow, the inclusion
of a 3D matrix is likely to elucidate the contribution of many niche components. To
accomplish this, much work must be done to determine the necessary signals that
should be included to model the bone marrow niche.
2.5 Publications relevant to this chapter
The material in this chapter has been adapted with minor modifications from the
following published article:
Jungwoo Lee, Meghan J Cuddihy, and Nicholas A Kotov. Three-dimensional cell




Poly(lactic-co-glycolic acid) Bone Scaffolds with
Inverted Colloidal Crystal Geometry
3.1 Introduction
Bone tissue engineering aims to replace traditional autograft and allograft repair
strategies with the implantation of mechanically functional biodegradable constructs
that support the wound site and hasten the natural repair mechanism until bone has
filled the defect [18] [85]. A number of structural criteria for implantable constructs,
scaffolds, are agreed upon, including sufficient porosity, interconnectivity, and me-
chanical properties. Porosity and complete interconnectivity throughout a scaffold
are necessary to promote uniform cell loading and migration, eventual tissue and
vasculature ingrowth, and sufficient nutrient diffusion and interstitial fluid and blood
flow [60, 119]. The ideal bone tissue engineering scaffold should have a precisely-
designed structure that provides complete interconnectivity of pores and maximum
load bearing capacity [55].
Traditional scaffold fabrication techniques, such as particulate leaching, gas foam-
ing, emulsion freeze-drying, electrospinning, and thermally induced phase separation,
are based upon bulk material alteration that yields a random pore structure [50–
53, 120]. The random pore distribution risks insufficient scaffold interconnectivity and
permeability; consequently, scaffold porosities often approach 95% to ensure complete
interconnectivity throughout the scaffold. Such high porosities present a dilemma in
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bone tissue engineering, where increased porosity enhances interconnectivity but de-
nies the scaffold of sufficient mechanical strength to support the load of the body until
tissue regeneration is complete. Therefore, there is a need for structural engineering
of bone scaffolds, providing sufficient control over 3D geometry [38, 91]. A systematic
approach to this problem would be the preparation of well-ordered porous materi-
als with tunable geometry. Computational image-based design/fabrication processes,
such as Solid Free-Form (SFF) Fabrication, provide precise control over scaffold archi-
tecture, including interconnectivity and geometry, but are limited in useable materials
and a minimum feature size of 100 µm [8, 38, 59, 60]. A method of producing scaf-
folds with highly controlled architectural properties on multiple scales would greatly
advance scaffold design for bone tissue engineering.
ICC scaffolds have emerged recently as a highly organized three-dimensional (3D)
environment for cell growth [26–29, 62, 63]. ICC scaffolds possess a hexagonally
close-packed (HCP) geometry, which can be described as closely packed spherical
cavities arranged in a hexagonal crystal lattice. The HCP arrangement offers a uni-
form cellular environment for differentiation and growth, as well as an ideal setting
for understanding the role of cell-cell and cell-scaffold interactions, and for com-
puter modeling of scaffold properties [62]. Additionally, HCP geometry guarantees
interconnectivity between all neighboring spherical cavities while calculations for the
maximum theoretical porosity for HCP structures range from 63-74% [63, 121]. The
high interconnectivity and low porosity of hydrogel HCP structures gave a ten to
one-thousand-fold greater relative stiffness than those predicted for bulk material al-
teration techniques in polyethylene glycol hydrogel scaffolds [63]. ICC structures can
be prepared of any bulk material, as long as a suitable pair of solvents is found: one
to dissolve the mold without disturbing the bulk material, and vice versa. Ideally,
specific design criteria, such as mechanical properties, degradation rate, and growth
factor release rate, can be met by adjusting scaffold material and the size of spheres
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that compose the mold.
Recently, our group has produced ICC scaffolds composed of sol-gel and polyacry-
lamide hydrogel [26–29, 62]. Several cell types were shown to attach and proliferate on
these structures, including human hepatic, bone marrow stromal, thymic epithelial,
and premeylote monocyte cells, and mouse fibroblastic and T-cells. The challenges
related to cell attachment typical for hydrogels were solved using layer-by-layer coat-
ing of their surfaces [27, 122]. The ICC structure offers some obvious advantages for
bone tissue engineering such as (1) high degree of structural control, (2) invariably
complete interconnectivity of cavities, (3) 3D geometry resembling the morphology of
trabecular bone and (4) the possibility of achieving high mechanical strength. Other
tangible advantages, which can come into play in future research, are the conve-
nience for tissue development simulation and incorporation of osteoconductive and
osteoinductive nanocolloids. From a fundamental point of view, the simplicity of ICC
preparation and high degree of structural control provide excellent opportunities for
understanding and manipulating cell culture on the scaffold.
Here, we introduce ICC scaffolds from a biodegradable polymer often used in
constructing bone implants. The key parameters examined here are the ability to
create highly ordered PLGA ICC scaffolds, the potential to control the diameter of
the cavities and the channels connecting the cavities, the compressive modulus of the
scaffolds, and the biocompatibility of scaffolds in vitro.
3.2 Methods
3.2.1 Preparation of CCs
One gram of uniformly-sized soda lime microspheres (Duke Scientific Corporation,
Palo Alto, CA) were added to ethylene glycol (Sigma, St. Louis, MO) in a dropper
bottle. Molds were assembled by securing a glass Pasteur pipette to a glass vial (7
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mm inner diameter) so that the pipette tip hung centered within the vial. Each mold
was filled with ethylene glycol and positioned in an ultra-sonic bath. Two drops of the
microsphere solution was dropped into the pipette every 15 min, so the microspheres
slowly settled onto the bottom of the vial and assembled into a CC under gentle
sonication. After the desired volume of microspheres was added to the mold, the
pipette was detached, and the microspheres and vial were left under sonication for
an additional hour. The vial was then heated at 160 ◦C overnight to evaporate all
ethylene glycol before heating for 3 hours to anneal the microspheres together, forming
a solid CC. CCs were constructed of 100, 200, and 330 µm microspheres to yield ICCs
with three different cavity sizes.
The annealing temperatures were adjusted in two separate experiments. In the
first experiment, the annealing temperature was varied to explore the controllability of
the diameter of interconnecting channels. Here, 100 µm microspheres were annealed
at 660, 670, 680, and 690 ◦C, 200 µmmicrospheres were annealed at 670, 680, 690, and
700 ◦C, 330 µm microspheres were annealed at 690, 700, and 710, and 720 ◦C. Based
on the result from the first experiment, six combinations of microsphere size and
annealing temperatures were chosen to produce scaffolds with different sized cavities
and interconnecting channels for cell culture. Microspheres with a 100 µm diameter
were annealed at 670 and 690 ◦C, while 200 and 330 µm microspheres were annealed
at 690 and 700 ◦C. These temperatures were chosen based on stability of CCs and
the variety of resulting channel sizes.
3.2.2 Preparation of ICC scaffolds
CCs were removed from vials, and placed into a 0.1 g/mL solution of 85/15 PLGA
(Lactel Absorbable Polymers, Pelham, AL) in methylene chloride. The CCs were cen-
trifuged for 10 min at 5900 rotations per minute (RPM) to infiltrate PLGA solution.
The infiltrated CCs were allowed to dry at room temperature overnight, and then
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placed under vacuum for 24 h. The edges of each infiltrated CC were scraped lightly
with a razor blade to remove surface PLGA and expose the microspheres. Next, the
infiltrated CCs were stirred in a 5% hydrofluoric acid (HF) solution for 2 days, chang-
ing HF solution once, and then stirred in a 1.0 N hydrochloric acid (HCl) solution
for one day. The HF/HCl cycle was repeated, rising with distilled H2O in between
cycles. To ensure all HF was rinsed from the scaffolds, resulting ICCs were washed
in phosphate buffered saline (PBS), changing solution until the pH remained stable
at 7.4.
3.2.3 Characterization of ICCs
The order, overall structure, and diameter of interconnecting channels were char-
acterized for scaffolds of 100, 200, and 330 µm cavity diameters. The HCP order of
CCs for each microsphere size was observed with scanning electron microscopy (SEM).
In the first annealing temperature experiment, ICCs were characterized with scanning
electron microscopy (SEM) to observe overall order and how the interconnecting chan-
nel size varied with microsphere annealing temperature. For each microsphere size,
two ICCs resulting from each microsphere size and annealing temperature combina-
tion were examined, and 10 interconnecting channels were measured on each scaffold.
The diameters of interconnecting channels were analyzed using SEM images using
the public domain National Institutes of Health (NIH) Image program (developed at
the U.S. NIH and available on the Internet at http://rsb.info.nih.gov/nih-image/).
3.2.4 Mechanical Properties
Four ICCs constructed from 100, 200, and 330 µm microspheres with annealing
temperatures of 670, 690, and 700 ◦C, respectively, were mechanically tested in com-
pression using a 100Q Universal Test System Mechanical Properties Tester (TestRe-
sources Inc, Shakopee, MN). ICCs were tested in a dry state at room temperature.
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The specimens were compressed at a rate of 0.01 mm/s, and the compressive modulus
was defined as the slope of the linear portion of the stress-strain curve.
3.2.5 Cell culture
Human fetal osteoblast (hFOB) 1.19 (CRL-11372) was purchased from American
Tissue Culture Corporation (ATCC) (Manassas, VA) and grown as recommended by
ATCC in 45% Ham’s F12 medium, 45% Dulbeccos modified Eagles Medium (DMEM)
and 10% fetal bovine serum (Gibco, Frederick, MD) supplemented with 1% antibiotic.
Cells were grown at 37 ◦C and 5% CO2, changing medium every 2-3 days.
3.2.6 Cell Loading and Culture on Scaffolds
Twelve ICCs, 7 mm in diameter and 1.2 mm in height, were constructed for
each of the six cavity size and annealing temperature combinations mentioned above.
Scaffolds were sterilized and wetted with ethanol for one hour. Scaffolds then were
centrifuged twice in fresh PBS at 900 RPM for five minutes before placing in a well
of a 12-well plate. hFOB 1.19 cells were stained with trypan blue (Sigma, St. Louis,
MO) and counted before suspending in medium and distributing into wells at 4.6x104
cells/scaffold. Cells and scaffolds were incubated at 37 ◦C and 5% CO2. Three
scaffolds of each cavity size and annealing temperature were removed at 1, 5, 9, and
12 days for viability staining and three scaffolds were removed for double stranded
DNA (dsDNA) quantification.
In a second set of cell culture experiments aimed at quantifying and examining
the osteoblast phenotype, twenty scaffolds of the following cavity sizes and annealing
temperatures were utilized: 100 µm, 670 ◦C; 200 µm, 690 ◦C; 330 µm, 700 ◦C.
Scaffolds were prepared as described above with ethanol and PBS treatment, and
then were placed into wells of a 96-well plate before cells were seeded at densities of
2.0×104 cells/scaffold. Scaffolds were inserted to 96-well plates because the scaffolds
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would cover the entire bottom area of the wells, increasing the consistency of cell
seeding into the scaffolds, rather than onto the bottom of the well plate. Cells were
incubated at 37 ◦C and 5% CO2. After one day, scaffolds were transferred to a 24-
well plate to increase the amount of media surrounding cells. Two scaffolds were
removed after three hours, and six scaffolds were removed on days 1, 4, and 7. At all
time points, two scaffolds were slated for F-actin and collagen type I staining, and
during the later three time points four scaffolds were slated for dsDNA and alkaline
phosphatase (ALP) activity.
3.2.7 Staining and Confocal Microscopy for Viability, F-actin, and Col-
lagen Type I
Cells on each of the three scaffolds removed at each time point for viability as-
sessment were stained with 2 µM calcein AM and 4 µM EthD-1 using a Live/Dead
Viability/Cytotoxicity Kit (Invitrogen Corporation, Carlsbad, CA).
Scaffolds for F-actin and collagen type I staining were fixed removed at each time
point, and fixed with 4% formaldehyde for 10 minutes at room temperature, rinsed
in PBS twice, permeablized with 0.1% Triton X-100 for 3-5 minutes, rinsed twice
more with PBS, and then immediately treated for visualization of collagen or F-
actin. Cells in scaffolds slated for F-actin staining were incubated for 30 min with
rhodamine phalloidin (Invitrogen Corporation, Carlsbad, CA). Scaffolds slated for
antibody immunohistological staining of collagen were stored in a 40 µg/mL solution
of biotin labeled polyclonal goat anti-collagen type I (Millipore, Billerica, MA) at
4 ◦C overnight. Samples were rinsed twice in PBS, and incubated in a 10 µg/mL
solution of FITC-Streptavadin (MP Biomedicals, Solon, OH) for one hour at 37 ◦C.
All samples were viewed immediately or stored at 4 ◦C protected from light, and were




Samples for SEM were fixed in 2%-volume gluteraldehyde solution overnight, then
washed in sodium cacodylate solution for 1 h. Samples were dehydrated through an
ethanol series with concentrations of 20, 50, 70, 90, and 100%, rinsing in each for
20 minutes. They were then freeze-dried and gold-coated. SEM observations were
performed using a FEI Nova Nanolab Dualbeam Focussed Ion Beam Workstation and
SEM at 15 kV.
3.2.9 dsDNA Quantification
Scaffolds slated for dsDNA quantification were washed with PBS, sonicated in
500 µL Passive Lysis Buffer (Promega Corporation, Madison, WI), and stored at -70
◦C until quantification, when samples were thawed and centrifuged for 10 minutes
at 10,000 rpm. Of the supernatant, 50 µL was prepared for dsDNA quantification
using Quant-iT PicoGreen dsDNA Reagent (Invitrogen Corporation, Carlsbad, CA),
according to manufacturer protocol. Sample fluorescence was measured at 520 nm
by excitation at 480 nm on a Biotek Synergy 2 Multi-Detection Microplate Reader
(Winooski, VT).
3.2.10 ALP Activity
ALP activity was assessed using a colorimetric endpoint assay measuring the
conversion of colorless 4-nitrophenyl phosphate (p-NPP) (Sigma, St. Louis) to 4-
nitrophenol (p-NP) (Sigma, St. Louis) by ALP [123]. Samples were lysed and cen-
trifuged as described above. Of the supernatant, 50 µL was used to quantify dsDNA,
and 10 µL was incubated with 40 µL p-NPP (20 M) for 30 minutes at 37 ◦C. The
reaction was stopped by the addition of 50 µL 0.1 N NaOH, and sample absorbance
was determined at 405 nm on a microplate reader. The activity of enzyme present
was quantified by comparison with a standard curve. ALP activity was normalized
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to cell number using dsDNA assay results.
3.2.11 Statistical Analysis
In all graphs, data is represented as the average of the indicated sample sizes ±
standard deviation. A Students t-test was performed to determine statistical signifi-
cance (p<0.05).
3.3 Results
3.3.1 Characterization of ICC Scaffolds
The chosen range of annealing temperatures was selected to provide a CC that is
stable enough to be handled and provide complete interconnectivity among adjacent
microspheres. The upper limit of the temperature range was chosen so that micro-
spheres were not completely melted, which would inhibit the infiltration of PLGA in
spaces between microspheres. Highly-ordered CCs were assembled from uniformly-
sized soda lime microspheres 100, 200, and 330 µm in diameter (Fig 3.1). For all
three sizes, microspheres were arranged in an HCP array, as observed in the struc-
ture cross-sections. After infiltration with PLGA, beads were completely removed
with HF/HCl, resulting in ICC structures with a similar degree of order to the CC
templates (Fig. 3.2). The cavities were uniform in size and showed interconnectivity
with all adjacent cavities.
3.3.2 Effects of Annealing Temperature on Channel Size
To explore the degree of control over the diameter of interconnecting channels by
CC annealing temperature, each microsphere size was annealed at four temperatures.
Several 100 µm CCs annealed above 690 ◦C were found to anneal to the vial that
served as the CC mold, and could not be removed for PLGA infiltration. It was as-
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Figure 3.1: SEM images of CCs with various cavity sizes. CCs are made from micro-
spheres of diameter (A) 100 µm, (B) 200 µm, and (C) 330 µm. Scale bar
= 200 µm.
Figure 3.2: SEM images of ICCs with various cavity sizes. SEM images of PLGA
ICCs resulting from CCs of microspheres of diameter (A) 100 µm, (B)
200 µm, and (C) 330 µm. Scale bar = 200 µm.
sumed that annealing above 690 ◦C caused excessive melting of 100 µm microspheres.
The edges of 200 µm CCs annealed below 670 ◦C crumbled when removed from the
vial mold; lower temperatures most likely did not cause sufficient annealing to provide
a secure structure for handling. For 330 µm microspheres, annealing temperatures of
670 and 680 ◦C were attempted, but the resulting CCs were not stable enough to be
handled without breaking; thus it was assumed that higher temperatures would be
explored. Additionally, as 330 µm CCs annealed at 720 ◦C were melted and cracked,
ICCs were not constructed at this temperature. ICCs from CCs of each microsphere
diameter and annealing temperature were characterized using SEM. The interstitial
30
channel diameters were measured to ensure sufficient size to allow cell migration
throughout the scaffold. Fig. 3.3 shows the average diameters for ICCs resulting from
each microsphere size and annealing temperature.
Figure 3.3: Interconnecting channel diameters as a function of microsphere sizes and
annealing temperatures.
3.3.3 Mechanical Properties
The compressive moduli of PLGA ICCs resulting from each microsphere size are
displayed in Table 3.1. The compressive moduli of ICCs with 100 and 200 µm cavity
diameters are slightly higher than those with 330 µm cavities.
Table 3.1: Compressive modulus of PLGA ICCs. PLGA ICCs were constructed using
100, 200, and 330 µm microspheres at the indicated annealing tempera-
tures (n=4).
100 µm, 670 ◦C 200 µm, 690 ◦C 330 µm, 700 ◦C
Compressive Modulus (MPa) 55.24 ± 17.57 63.63 ± 14.47 54.80 ± 30.98
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3.3.4 dsDNA Quantification
Two annealing temperatures were chosen for each cavity size to determine the
effects of cavity and channel diameter on osteoblast cell culture. dsDNA quantification
for each of these six scaffold cavity and annealing temperature sizes is displayed in
Fig. 3.4 for up to 12 days. There is a trend towards greater cell numbers with increased
cavity diameters, and proliferation does not seem significant over the culture period.
Figure 3.4: dsDNA content in scaffolds. dSDNA present in scaffolds (n=3) of dif-
ferent cavity and interconnecting space diameters for culture up to 12
days. (*Statistically significant (p<0.05) as compared to 100, 39 for the
indicated culture period; **Statistically significant (p<0.05) as compared
to 100, 42 for the indicated culture period; *** Statistically significant
(p<0.05) as compared to 200, 67 for the indicated culture period; ****
Statistically significant (p<0.05) as compared to 200, 85 for the indicated
culture period; ***** Statistically significant (p<0.05) as compared to
330, 105 for the indicated culture period.)
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3.3.5 Biocompatibility of PLGA ICC Scaffolds
Confocal microscopy and SEM images of hFOB 1.19 cultures on scaffolds 1, 5,
9, and 12 days after seeding onto the scaffolds revealed attachment, viability and
proliferation of human osteoblasts for up to 12 days on the scaffolds, as displayed in
Fig. 3.5. Most cells retained viability for the duration of the culture period. SEM
images, Fig. 3.6, reveal variety in cell morphologies, ranging from fully spread and
attached cells, to rounded cells with less area of attachment. Confocal microscopy
images of F-actin staining by rhodamin phalloidin for cell cultures of 3 hours, and
1 and 4 days are shown in Fig. 3.7. F-actin staining reveals that at 3 hours cells
are rounded, as they have likely not attached to the scaffold, and most F-actin is
localized near the cell membrane. After one day, cells have attached to the scaffold
and show more uniform F-actin distribution, as their cytoskeletal structure is spread,
indicating interaction and contact with the scaffolds.
3.3.6 Maintenance of Osteoblast Phenotype
Anti-collagen antibody staining is displayed in Fig. 3.8. Collagen type I antibody
staining did not reveal any collagen in the structure at day 1, but by day four a
presence of collagen was observed within or outside of cells, indicating an osteoblast
phenotype. ALP activity for each scaffold cavity size at 1, 4, and 7 days are displayed
in Fig. 3.9. ALP activity, however, seems slightly higher for greater cavity sizes, and
an upregulation was observed over time.
3.4 Discussion
The internal architecture of a scaffold defines the fundamental characteristics of
the construct. For example, the surface area for cell migration and proliferation, void
volume for tissue and vascular invasion in vivo, and bulk scaffold, i.e. mechanical,
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Figure 3.5: Confocal microscopy images of ICC cell cultures. Confocal microscopy
images of hFOB 1.19 culture on ICCs of cavity and annealing tempera-
tures of, (A) 100 µm, 670 ◦C (B) 200 µm, 700 ◦C (C) 330 µm, 700 ◦C,
(D) 100 µm, 690 ◦C, (E) 200 µm, 700 ◦C, (F) 330µm, 700 ◦C. Images (A)
(C) are of cultures after 1 day, and (D) (F) are images taken after 12
days of culture. Scale bar = 200 µm.
properties are all defined by the geometry of a scaffold [56, 124–126]. Control over
scaffold internal architecture is important to meet specific design criteria [127, 128].
Principally, we aimed to prove control over scaffold cavity size and the size of the
interconnecting channels between cavities, which directly relate to surface area, void
volume, and mechanical properties.
The cavity and interconnecting channel sizes of ICCs primarily are controlled by
microsphere size, HCP arrangement, and CC annealing temperature. Unlike hydro-
gel, PLGA does not significantly expand into cavities when microspheres are removed;
therefore, the microsphere diameter accurately defines the resulting cavity diameter.
The combination of HCP structure and microsphere annealing provides full intercon-
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Figure 3.6: SEM images of cells on ICCs. SEM images of hFOB 1.19 on ICCs demon-
strating variety of cell morphologies. Cavity diameters and annealing
temperatures for pictured scaffolds are (A) 200 µm 690 ◦C, (B) 330 µm,
690 ◦C. Both images are after 5 days of culture.
nectivity throughout the ICC scaffold. The highly ordered structure of CCs guaran-
tees connectivity of each cavity to 12 neighboring cavities. Annealing not only gives
stability to the CC structure, but also provides the sites of connection between cavities
in ICCs. Annealing temperature regulation is essential to ensure complete PLGA in-
filtration, scaffold interconnectivity, and to regulate the interconnecting channel size.
Pore size is of interest in controlling tissue growth, particularly bone, into scaffolds
[129, 130]. In vivo, it is generally believed that bone ingrowth and vascularization is
maximized over fibrous or connective tissue ingrowth in scaffolds in pore diameters
greater than 100 µm [131, 132]; however, this has been debated with research indi-
cating that smaller pore diameters encourage bone growth [133]. Others have shown
that bone growth occurs via chondrogenesis in 100 µm pores within hydroxyapatite
scaffolds, yet with 350 µm pores osteogenesis directly occurs [134–136]. In vitro, it
has been shown that larger pore sizes correlate with earlier osteoblast differentiation
[125]. There is a need for a systematic method of varying pore diameters to determine
optimal bone growth conditions.
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Figure 3.7: Confocal microscopy images displaying actin cytoskeleton. Confocal mi-
croscopy images of hFOB 1.19 on ICCs stained for actin after (A) 3h
(inset, greater magnification of bottommost cell in image), (B) 1 day, and
(C) 4 days.
In this study, diameters of 100, 200, and 330 µm were chosen to demonstrate the
ability to construct PLGA ICCs with a range of cavity diameters that would support
nutrient and waste diffusion and convection in vitro and in vivo, as well as tissue and
vascular in-growth in vivo. Additionally, architectures in this range have been shown
to promote osteoblast or bone growth [94, 137].
For each cavity size, the interconnecting channels were large enough to facilitate
cell migration throughout the scaffold. Although there is some overlap in the size
of interconnecting channels at different annealing temperatures, there is an obvious
trend of increased annealing temperature causing increased interconnecting channel
diameters. This is important for this type of scaffolds because this experiment demon-
strates that both the diameter of the cavities and the diameter of channels connecting
them can be controlled during the preparation of the scaffold. The increase of channel
diameters is caused by greater melting of microspheres at higher temperatures, pro-
viding a greater void space between cavities. It is noted that a slightly greater range
of channel diameters exists for each temperature with 330 µm microspheres. This
is most likely due to the increased size distribution of 330 µm microspheres (4.9%)
over that of 100 µm (3.1%) and 200 µm (2.9%) microspheres, which will cause less-
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Figure 3.8: Confocal microscopy images displaying collagen type I secretion. Confocal
microscopy images of hFOB 1.19 on ICCs stained for collagen type I after
four days of culture. (A) Scale bar = 40 µm. (B), (C) Scale bar = 80
µm.
ordered packing and a less consistent degree of contact between microspheres in CCs.
Additionally, the increased microsphere size causes faster settling of microspheres
during CC construction, which may hinder ordered packing, despite sonication. In
each case, the range of interconnecting channel diameters may also be attributed to
uneven heat distribution throughout the CC. Adjusting the time of annealing may
increase the control over degree of annealing to decrease the variation in intercon-
necting channel diameters. Despite the range of interconnecting channel diameters,
the general linear increase in channel diameter with increased annealing temperature
demonstrates an additional level of control over ICC scaffold properties that has not
been demonstrated in many other scaffold fabrication techniques.
The targeted functional outcome of bone tissue engineering is to produce a scaffold-
cell construct that has mechanical properties supporting the loads of daily life [138].
Overall, the ICC geometry possesses an advantage over traditional porous scaffolds
because of its complete interconnectivity at lower porosities. The compressive moduli
are greater than those of other porous PLGA scaffolds fabricated using a stochastic ar-
rangement of porogens [139, 140]. In fact, the compressive moduli of the scaffolds are
in the range of other polymer scaffolds fabricated using SFF, which can be designed
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Figure 3.9: ALP activity in scaffolds. ALP activity measured in scaffolds (n=4), nor-
malized by dsDNA levels in scaffolds. (*Statistically significant (p<0.05)
as compared to day 1; **Statistically significant (p<0.05) as compared to
days 1 and 4 for the indicated cavity diameter).
to meet specific mechanical properties [56, 141]. Considering the majority of current
scaffolds are now composed of composite materials to increase mechanical properties,
the ICC scaffolds have great potential to approach the mechanical properties of bone.
Improved mechanical properties may be obtained by additional infiltration steps or
infiltrating with a stronger biodegradable composite material. An additional infiltra-
tion step for the 330 µm or greater CCs may be especially advantageous in obtaining
morphological similarity to trabecular bone, which has trabeculae of 80-280 µm in
thickness and over 450 µm separation between trabeculae [142].
Confocal microscopy images reveal that cells were able to attach and inhabit the
ICC scaffolds for up to 12 days, and the abundance of calcein AM stained cells (green)
indicate viability was strong. Cell survival over several weeks is especially important
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to establish because of the harsh acid treatment required to remove the microspheres.
Note in Figs. 3.5(E) and (F) how cells have begun to coat the cavity walls and appear
to have infiltrated beyond the outer layer of cavities.
The variety of cell morphologies displayed in Fig. 3.6 indicates that although
cells adhere to the PGLA ICC scaffold, cell adhesion could be improved to achieve
more consistently spread morphologies. Increased cell attachment will also encourage
cell migration within the scaffold, yielding a more uniform population throughout
the structure. F-actin staining revealed that the rounded morphologies with actin
localized to the cell membrane were demonstrated at times close to seeding, and
that flattened morphologies with a uniform cytoskeleton were observed after a day.
The rounded morphologies observed in SEM images may be cells that have recently
attached, migrated, or replicated. Still, collagen was not observed at 3 h or 1 day after
seeding, indicating that surface modification that enhances or speeds cell spreading
may be beneficial in increasing bone production within the scaffold.
The dsDNA assay revealed a trend that greater cell numbers could be found on
scaffolds of greater pore sizes, likely because as the pore sizes and interconnecting
channel sizes are increased, the cavity openings on the surface of the scaffold are
larger, leading to greater cell seeding efficiency. Additionally, there was a trend toward
greater ALP activity with greater cavity sizes, as well as increased ALP activity
over time. ALP activity was normalized to dsDNA, indicating that cells were more
active over time and the increased activity was not due to greater numbers of cells
present. As more cells could be seeded into larger pores, perhaps their proximity
within spherical pores signal osteogenesis. Additionally, the greater pore sizes likely
allow for greater circulation of nutrients, signaling factors, and metabolites. The
theoretical porosity should remain the same despite scaffold pore size, but the degree
of order may vary slightly with the different size distribution of beads. As well, the
permeability of the different cavity sizes was not measured here. These measurements
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may further explain the increased viability of the cells in larger pore sizes.
As the quantity of dsDNA did not increase greatly over time for most cavity and
interconnecting channel sizes (Fig. 3.4), it is likely that cells were in an osteogenic
state, rather than a proliferative state. Low proliferation, increasing ALP activity
over time, and the presence of collagen type I are important parameters to consider
particularly when utilizing the hFOB 1.19 pre-osteoblast cell line, as these parameters
are indicators of osteoblast differentiation and mineralization [123, 143, 144]. As
this cell line has a temperature dependent phenotype, meaning that at 33.5 ◦C cells
rapidly replicate, and at 39.5 ◦C cells display little or no cell division [145]. In these
studies, it was indicated that at the incubation temperature used, 37 ◦C, there low
cell replication as well as indicative factors of bone production.
These studies support conclusions that cavity sizes greater than 100 µm are ideal
for bone growth, but further study must be performed. Still, one must also remember
that with greater pore sizes, mechanical properties are likely to decrease. In vivo
studies may be more indicative of effects of scaffold feature sizes, as greater quantities
of cells, tissues, and circulating fluids are in contact with the scaffold than during in
vitro studies.
3.5 Conclusions
A new geometry of biodegradable ICC scaffolds was demonstrated with consistent
geometries and cavity sizes of 100, 200, and 330 µm. These studies indicated trends
that greater pore sizes may increase cell growth and bone production. PLGA ICC
scaffolds have great potential for bone tissue engineering applications because they
possess a regular structure for high mechanical properties and uniform cell loading
and retention. The spherical cavities also provide maximal surface area and variable
diameters to support tissue and vascular invasion.
The ICC structure has broad applications in bone tissue engineering in that it can
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be incorporated into molds with more complex geometries designed to fit anatomical
shapes, for robust mechanical properties, or with architectures ideal for tissue inva-
sion. For example, the ICC structure can be incorporated into molds designed with
complex internal architecture for increased mechanical functionality and made using
SFF fabrication methods. This incorporation can take advantage of the mechanical
and geometric functionality of the SFF scaffold, while increasing its surface area and
topography. For this application, CC construction with smaller microspheres might
be desired to facilitate increased order when depositing microspheres into molds with
their own internal architecture, while providing larger pores in between struts with
ICC internal geometries.
3.6 Publications relevant to this chapter
The material in this chapter has been adapted with minor modifications from the
following published article:
Meghan J Cuddihy and Nicholas A Kotov. Poly(lactic-co-glycolic acid) bone scaf-




In vitro Analog of Human Bone Marrow from 3D
Scaffolds with Biomimetic Inverted Colloidal
Crystal Geometry
4.1 Introduction
The expansion of human hematopoietic cells ex vivo is vital for their use in cellu-
lar therapies, as well as in the development of immune therapeutics such as human
monoclonal antibodies. As well, as most information on HSC renewal and lineage
commitment has been based primarily on mouse models, which do not entirely accu-
rately represent the human body, artificial analogs of the HSC niche can contribute
to knowledge of interactions between HSCs and the surrounding stromal cells and
matrix. These understandings can be extremely valuable in the situation of phar-
maceutical drug testing, where one could observe any effects on HSCs or the niche
before testing in vivo.
Construction of such ex vivo analogs is quite challenging due to the complexity
of the human bone marrow microenvironment [146]. Here, stromal cells play a crit-
ical role in both presenting membrane-bound ligands and secreting soluble signaling
molecules. HSC differentiation is strongly dependent on cellular interactions with
stromal tissue and appropriate levels of signal proteins [116, 146–153]. Although the
native bone marrow environment can be recreated on 2D culture to some extent by
the addition of proper cytokines and growth factors and/or by the presence of co-
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cultured stromal or feeder cells [109, 110, 147, 148, 152, 153], it is inefficient for the
purpose of replicating hematopoiesis in lacking the dimensionality and ECM compo-
nents of the HSC niche. Furthermore, 2D cultures have cell-cell contacts only in one
direction. Utilizing 3D cell cultures that induce more intensive cell-to-cell contacts
between HSCs and stromal cells appears promising to produce the appropriate devel-
opmental niches for stem cells [8]. For example, generation of human T lymphocytes
from human CD34+ cells in vitro was made possible without exogenous cytokines or
stromal cells due to 3D organization of the cell scaffold [4].
A 3D matrix ideal for mimicking the HSC niche in bone marrow, specifically for
drug testing, must be porous, have a controllable structure, and be made of a trans-
parent material. Porosity and complete interconnectivity allows for cell migration,
as well as nutrient, waste, and cytokine diffusion. A controllable structure allows
the user to design the intensity of cell-cell contacts, as well as minimizes variation
between scaffolds, thereby reducing experimental variability. Transparency is useful
in observing the cells through microscopy. With these characteristics in mind, the
Kotov group developed the hydrogel ICC scaffolds. ICC scaffolds have a geometry of
highly-ordered and uniformly-sized spherical cavities. The cavity size can be easily
changed to vary the degree of cell-cell contacts. Each cavity is connected to twelve
surrounding cavities, which allows for cell migration and diffusion of cytokines and
media. The transparent hydrogel allows the user to view cells within the scaffolds us-
ing a simple optical microscope or by tagging the cells with a fluorophore and viewing
with a fluorescent microscope.
Our approach for the replication of bone marrow utilized hydrogel ICC scaf-
folds with feeder cells to demonstrate substantial expansion of CD34+ HSCs. Here,
the feeder cells chosen were the human stromal (HS)-5 bone marrow stromal cell
line. HS-5 cells were developed from bone marrow specifically for the support of
HSCs [109, 110]. HS-5 cells were shown to produce high levels (¿1000 pg/mL) of
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growth factors interleukin-6 (IL-6), IL-8, granulocyte colony-stimulating factor (G-
CSF), and macrophage-inhibitory protein-1 alpha and also produced detectable levels
of granulocyte-macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF), Kit ligand
(KL, also called stem cell factor (SCF)), IL-1α, IL-1β, IL-1RA, IL-11, and leukemia
inhibitory factor (LIF) [109]. Next, B lymphocyte differentiation was demonstrated
with the production of functional B cells and their expression of key signal proteins,
class switch of cells from immunoglobulin M (IgM) to immunoglobulin G (IgG). Fur-
ther evidence of production of functional B cells, such as secretion of influenza A
specific antibody, and production of human immune cells in SCID mice after subcu-
taneous implantation of the designed scaffolds, are presented in a paper by Nichols
et al [30], but are outside of the realm of this dissertation.
4.2 Methods
4.2.1 ICC scaffolds fabrication
CCs were prepared as previously reported [27]. Briefly, a plastic mold (diame-
ter (D) = 6.5 mm) was connected to a long Pasteur glass pipette and was partially
immersed in an ultrasonic water bath. Two to three drops of polystyrene beads (D
= 100 µm, Duke Scientific) suspended in ethanol were released through the Pasture
pipette in 20 min time intervals under gentle agitation generated by the ultrasonic
water bath until the thickness approximately reached 0.5-1 mm. The beads were
completely dried at 60 ◦C overnight, and then the CCs were annealed at 120 ◦C for
4 h. Final dimensions of freestanding CCs were 6.5 mm in diameter and 0.5-1 mm
in thickness. Scaffolds were manufactured composed of either silicate or hydrogel.
For silicate scaffolds, sodium silicate solution (14% NaOH, 27% SiO2) (Sigma) was
diluted with water to a 1:1 ratio with deionized water, and then infiltrated into the
CCs by centrifugation at 5800 RPM for 30 min. After that, the composite CCs were
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dried overnight in the air to let the sol become a gel. Final silicate ICC scaffolds were
obtained after removing the CC template either burning out at 600 ◦C for 30 min or
dissolving by tetrahydrofuran (THF) [33]. For hydrogel scaffolds, hydrogel precur-
sor solution composed of 30% (w/w) acrylamide monomer, 5% (w/w) bis-acrylamide
cross-linker, and 0.1% (v/v) N,N,N,N-tetramethylethylene-diamine accelerator was
prepared with nitrogen gas purged deionized water. The precursor solution was infil-
trated into the CC by centrifugation at 5800 RPM for 10 min, and 1% (w/w) potas-
sium peroxide initiator solution was added. After complete polymerization within
2-3 h at room temperature, the CC containing hydrogel was cut out and immersed in
tetrahydrofuran for 24 h to remove the template. Finally the hydrogel ICC scaffolds
were washed and equilibrated in deionized water. All chemicals were purchased from
Sigma.
4.2.2 LBL surface modification
The surface of polyacrylamide hydrogel ICC scaffolds was coated with sequen-
tial layers of negatively charged 0.5% (w/w) clay platelets (average dimension of
1 nm thickness and 70-150 nm in diameter, Southern Clay Products) and posi-
tively charged 0.5% (w/w) poly(diallyldimethylammonium chloride) (PDDA) (MW =
200,000) (Sigma) solution utilizing a LBL surface coating technique. The LBL coat-
ing was started with a PDDA layer. At first, hydrogel ICC scaffolds were immersed
in PDDA solution for 15 min and rinsed in deionized water for 30 min. Then the
scaffolds were immersed in clay solution for 15 min and rinsed with deionized water
for 30 min. This LBL coating cycle was repeated five times. The outermost layer
was clay nanoparticles. To demonstrate 3D LBL coating on hydrogel ICC scaffolds,
fluorescein isothiocyanate (FITC) conjugated albumin (Sigma) which has negative
charge was used instead of clay nanoparticles. A hydrogel ICC scaffold coated with
ten bilayers of FITC-albumin and clay nanoparticles was imaged using the confocal
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microscope with 10× objective. Confocal series images taking 160 µm depth were
three-dimensionally reconstructed using imaging software.
4.2.3 Bone marrow stromal cell culture
HS-5 (CRL-11882) and hFOB 1.19 cell line (CRL-11372) were purchased from
ATCC (Manassas, VA). Culture media for HS-5 was composed of Dulbeccos modified
Eagles medium (DMEM) with 4 mM L-glutamine, 4.5 g/L glucose, 1.5 g/L sodium bi-
carbonate, 10% (v/v) fetal bovine serum (FBS), and 1% (v/v) penicillin-streptomycin
(all reagents purchased from ATCC). The hFOB cells were cultured with 45% Hams
F12 medium, 45% DMEM, 10% FBS and 1% antibiotic. The cultures were main-
tained in a T-25 culture flask at 37 ◦C with 5% CO2 in high humidity condition.
Once cell growth reached approximately 80% confluence, they were detached from
the culture flask using 0.25% (v/v) trypsin-EDTA solution and 105 cells were seeded
on top of UV sterilized scaffolds which were placed in a 96-well plate. Culture volume
was maintained 250 mL and media was changed every other day.
In order to characterize stromal cell growth in 3D scaffolds, HS-5 cells were
stained with 5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molec-
ular Probes) [34]. 105 pre-stained HS-5 cells were seeded on silicate scaffolds and
cultured for 5 days. The cells growing within silicate scaffolds were imaged under a
Leica SP2 confocal microscope with 20× objective. A 488 nm laser was used for exci-
tation and emission signals were collected within 515-550 nm window. Transmission
image was over-laid with fluorescent image to designate the location of cells within
pores.
4.2.4 Human CD34+ HSCs isolation
Peripheral blood buffy coats were obtained from Gulf Coast Blood Bank or from
donors (18-50 years of age) after informed consent under protocols that were re-
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viewed by the Institutional Review Board of The University of Texas Medical Branch.
Cord blood and bone marrow were purchased from Lonza Inc. (Allendale, NJ). The
mononuclear leukocyte fraction was isolated from these three CD34+ HSC sources
using Ficoll density gradient separation medium as described by the manufacturer
(Amersham-Biosciences, Piscataway, NJ). CD34+ HSCs were enriched by counter
current centrifugal elutriation of mononuclear leukocytes in a Beckmann J6M elu-
triator (Beckman Instruments, USA) using a Sanderson chamber. A Masterplex
peristaltic pump (Cole Parmer Instruments) was used to provide the counter current
flow. RPMI 1640 supplemented with 2 mM glutamine, 100 units penicillin G and 100
mg/mL streptomycin and 10% heat inactivated defined fetal calf serum (Hyclone,
Logan, UT) was used as elutriation medium. 3-6 × 106 cells were loaded at 3000
RPM and HSCs were isolated using a step-wise reduction of rotor speed until the
appropriate cell diameter population, 6-7 mm, of CD34+ enriched cells was collected.
Immunophenotypic analysis of elutriation with 5-7 µm diameter HSCs at the time
of isolation and seeding of the scaffold showed that these cells were lineage cocktail 1
(lin1) mature marker negative, CD34+ cells were further purified by negative selection
of any remaining lin1 positive or mature cell types using Dynall magnetic beads or
by flow cytometric cell sorting using a FACSaria cell sorter.
4.2.5 Human CD34+ HSCs expansion
CD34+ cells were labeled with the CFSE dye as previously described [34]. Scaffolds
were then seeded with 1-4×104 CFSE-labeled CD34+ HSCs in 50 mL of DMEM
containing 5% pluronic F-127 on the bottom of a 24-well tissue culture plate. A
total of 3-5 scaffolds were placed in a standard 2-10 mL plastic bioreactor chambers
mounted on a rotary bioreactor (Synthecon, Houston, TX) with a rotational speed
of 5 RPM in the same media. In a subset of experiments matrices were seeded with
stromal support cells from human bone marrow aspirates and non-autologous HSCs
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were added after 2 days of stromal culture. HSC/stromal cell cultures were also
incubated in plastic Petri dishes in order to allow us to evaluate 2D versus 3D cell
culture.
4.2.6 Inducing B cell differentiation
To induce HSC differentiation, a co-culture of HS-5 and hFOB1.19 cell line was
initially used. Although differentiation was successful these cell lines quickly over-
grew the matrix without irradiation and thus were somewhat inconvenient. Later,
primary cell lines were created from bone marrow aspirates which included cells
positive for CD105 (100%), CD166 (100%), CD44 (95%), CD14 (1%), CD34 (1%)
and CD45 (<1%) suggesting they were part of the stromal cell population; at least
one cell type in the support cell mix was of osteoblast lineage as it was positive
for osteonectin. These primary support cells formed densely populated layers sim-
ilar to natural bone marrow and replicated the actual bone marrow environment
better than the feeder layer made from a single cell type. Growth factors used to
promote hematopoiesis included: interleukin IL-2 (5 ng/mL, Calbiochem), IL-7 (20
ng/mL, R&D Systems), Flt3 ligand (20 ng/mL, Chemicon), stem cell factor-1 (SDF-
1, 20 ng/mL, Calbiochem), BMP-4 (4 ng/mL, R&D Systems), and IL-3 (10 ng/mL,
Chemicon). Additives used to promote development of a B lymphocyte lineage in-
cluded: soluble CD40L (5 ng/mL, Invitrogen), IL-4 (10 ng/mL, Calbiochem), IL-5
(10 ng/mL, Chemicon), IL-6 (10 ng/mL, Calbiochem), IL-10 (10 ng/mL, Chemicon),
IL-2 (5 ng/mL, Calbiochem), IL-7 (20 ng/mL), Flt3 ligand (20 ng/mL), stem cell-
derived factor (20 ng/mL, Chemicon), IL-3 (10 ng/mL) and agonist anti-CD40 mAb
(5 mg/mL, clone HM40-3; BD Biosciences).
Cultures were exposed to 3.5 mg/mL lipopolysaccharide (Sigma-Aldrich) to acti-
vate B lymphocytes and induce plasma cell formation. Secreted IgM was quantitated
for all B cell cultures using a total human IgM ELISA assay (Diagnostic Automaton,
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Inc.) as described by the manufacturer. Supernatant fluids were removed from 3D
and 2D cultures and levels of secreted IgM were determined. All samples were run
in triplicate and averaged optical densities at 450 nm were compared to a standard
curve using optical densities obtained for each of the standards.
4.3 Results
4.3.1 ICC scaffolds
The matrices described here are ICC scaffolds, which were recently introduced
[33,38]. The template for the ICC scaffolds were hexagonally-packed lattices of
uniformly-sized (110 µm) microspheres (Fig. 4.1A). The resulting ICCs presented
a similar structure of a hexagonally-packed lattice of cavities, with hydrogel filling in
the spaces in between the microspheres of the template Fig. 4.1B). The channels that
connected the cavities measured approximately 10-20 µm.
Figure 4.1: SEM images of (A) a CC composed of polystyrene microspheres and (B)
an ICC composed of silicate hydrogel.
To provide adequate adhesion of bone marrow support cells, hydrogel matrices
were coated by clay and PDDA multilayers via LBL technology [154], which results
in a thin layer of nanocomposite on the walls of the scaffold [27] (Fig. 4.2). Fig. 4.2A
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presents the overall concept of LBL, where a substrate is dipped first into a charged
aqueous solution, and then rinsed so that only one monolayer of the charged substance
remains. The solution may be of any charged substance that can form a solution in
water; e.g. polymers, nanoparticles, or proteins. Next, the substrate is dipped into an
aqueous solution of the opposite charge, which is then rinsed so that one monolayer
adheres. This cycle completes one bilayer, and it can be repeated until as the desired
number of bilayers have adsorbed onto the surface. Fig. 4.2B is a schematic of the
clay/PDDA layers, and Fig 4.2C is an atomic force microscope (AFM) image of the
clay/PDDA layers on a silicon wafer [154]. Fig 4.2D demonstrates LBL on an ICC
scaffold through 5 layers of FITC-labeled albumin and PDDA.
Figure 4.2: Schematic of LBL surface coatings and its applications on ICC scaffolds.
(A) Schematic of LBL on a flat substrate. (B) Illustration of clay/PDDA
LBL on a flat substrate [154]. (C) AFM image of PDDA/LBL on a silicon
wafer. (D) 3D reconstruction of an ICC scaffold coated with five layers
of FITC-labeled albumin and PDDA. Scale bar = 100 µm.
4.3.2 HSC niche
Human bone marrow stromal cells were seeded on scaffolds and cultured for 3
days to allow the formation of a support cell layer on the scaffold surface prior to
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the addition of CD34+ HSCs. Bone marrow stromal cells were stained for expression
of the cell marker CD105 to allow for visualization of the stromal cell network that
was formed by day 3 (Fig. 4.3A). On day 3 CD34+ were then seeded onto stromal
cell/ICC constructs (Fig. 4.3B). HSCs were isolated from human peripheral blood
(PB), umbilical cord blood (CB) or bone marrow (BM). All cells were positive for
CD34 and were lin1 negative when seeded onto the scaffolds. Analogous cultures
were also made on 2D plates to establish the importance of the 3D geometry in ICC
scaffolds. Examination of ICC cultures on day 28 showed the continued presence
of CD34+ HSCs (red) (Fig. 4.3C); CD34+ antibody-labeled cells (red) are shown
interacting within the scaffold with CD105+ stromal cells (green).
Figure 4.3: Confocal microscopy images of stromal- HSC interactions. (A) Stromal
cells after 3 days of culture, stained for CD105 (green). (B) CD34+ cells
(red) interacting with stromal cells (green) after 1 day of culture. (C)
Interactions between CD34+ cells (red) and stromal cells (green) after 28
days of culture.
Data from flow cytometry show that there were significantly higher percentages
of CD34+ cells in ICC cultures after 28 days, regardless of the original cell source,
when compared to 2D plate cultures (Figs. 4.4A-F). Figs. 4.4A-C correspond to 3D
ICC cultures, while Fig. 4.4D-F correspond to 2D plate cultures. Cells in cultures
Fig. 4.4A and D, B and E, and C and F were isolated from bone marrow, cord blood,
and peripheral blood, respectively. A significantly greater percentage of cells in ICC
scaffolds expressed CD34 (red) over the isotype control (green line). These data are
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summarized in Fig. 4.4G. This demonstrates that an undifferentiated population of
CD34+ cells was maintained over time and demonstrates the importance of the chosen
3D ICC organization of the cell cultures for replication of reproductive functionality
of bone marrow. This is also supported by the loss of CFSE fluorescence intensity
(Fig. 4.4H), where the percentage of CFSE loss corresponds to the proliferation of
the cells labeled with it (CD34+).
Figure 4.4: Flow cytometry results from CD34+ expansion after 28 days. (A-F) His-
tograms representing cells stained for CD34. Red histograms represent
cells that stain positive for CD34, green represents the isotype controls.
(A-C) 3D ICC cultures. (D-F) 2D plate cultures. Cells in A and D, B
and E, and C and F were sourced from bone marrow, cord blood, and
peripheral blood, respectively. The percentages indicated on each plot are
the percentage of cells that express higher intensity for the CD34 marker
when compared to the isotype control. (G) Summary of percentages of
cells positive for CD34. (H) Loss of CFSE fluorescence intensity.
To assess the ability of the artificial bone marrow constructs to produce functional
immune cells, we focused on B lymphocyte production since B cells normally undergo
the process of differentiation (as well as negative and positive selection) in the bone
marrow [148, 153, 155, 156]. After 3 days of culture, ICC/stromal cell constructs
containing growth factors to drive the B cell differentiation were seeded with CD34+
HSCs isolated from umbilical cord blood. Cell cultures were examined for stage-
specific markers of development and functionality on days 1, 7, 14, 28 and 40. ICC
cultures showed nuclear specific expression of recombination activating gene-1 protein
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(RAG-1), which is expressed in developing B and T lymphocytes, by day 7 (Fig. 4.5A).
Also seen by day 14 (Fig. 4.5B) was cell surface expression of IgM (green) and CD19
(red), indicating differentiation of the CD34+ HSC into B cells. Co-expression of IgM
(green) with IgD (red) was seen by day 28 (Fig. 4.5C) confirming differentiation of
CD34+ into mature antigen-naive B lymphocytes. Averaged data for cells from six
different donors evaluating expression of CD40, IgD, IgM as well as co-expression of
IgD and IgM are displayed in Fig. 4.5D and show the comparison between 3D and
2D cultures. Expression of CD40 (P = 0.0002) and IgM/IgD co- expression (P =
0.021) was significantly higher in donor matched ICC cultures than in 2D cultures
(Fig. 4.5D).
4.4 Discussion
The open geometry of the ICC lattice, high porosity (74% free space), full inter-
connectivity, and large surface area made ICC scaffolds an attractive structure for
the studies of 3D effects in cell cultures. The ICC structure (Fig. 4.1) is geometrically
similar to that of trabecular bone, which is important for creation of the microenvi-
ronmental niches that maintain stem cell survival and promote maturation [157–159].
As the beads provide a template for the scaffold cavities, the diameter of the beads
is directly proportional to the diameter of the resulting cavities. Similarly, the size
of channels connecting the cavities can be tuned by the bead diameter, as the degree
of contact upon annealing is greater for larger beads, and also by annealing tem-
perature and time [25]. This bead diameter was chosen because it provides efficient
contacts between adhesion and dispersion cells [62], and allows for natural cell migra-
tion through the channels between the cavities, which is imperative for replication of
hematopoietic tissues. The materials of a typical ICC scaffold used here can be either
silicate or polyacrylamide hydrogel, both of which were demonstrated to be compat-
ible with human cell cultures [26, 27, 29]. Lastly, dynamic culture within a rotary
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Figure 4.5: Results of B cell differentiation. (A-C) Confocal microscopy images of
cultures in ICC scaffolds. (A) Expression of Nuclear RAG-1 (red) and
surface expression of IgM (green) on day 7. (B) Cell surface expression
of CD19 (red) and IgM (green) on day 14. (C) Expression of IgM (green)
and IgD (red) on day 28. In all images, blue indicates DAPI nuclear stain.
(D) Flow cytometry results quantifying percentage of cells expressing IgM,
IgD, and CD40 for plate and ICC cultures.
cell culture vessel was beneficial not only by creating a more realistic physiological
environment but also by maximizing the role of specifically designed ICC geometry
by generating continuous convective media flow into ICC pores.
To facilitate cellular adhesion to the hydrogel, ICC scaffolds were coated with a
LBL-applied nanocomposite of clay/PDDA (Fig. 4.2). The nanoscale nature of the
coating is essential for several reasons. (i) The hybrid organic-inorganic composite is
mechanically compatible with the hydrogel and does not delaminate. (ii) It provides
high Youngs modulus [29] necessary for successful stromal cell adhesion [16, 160].
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(iii) Nanocomposites have minimal light scattering because the characteristic diame-
ter of the inorganic component is smaller than the wavelength of light, which is quite
relevant for optical interrogation of biological processes. These features markedly dif-
ferentiate ICC hydrogel scaffolds from those previously used for bone marrow cultures.
In fact, the nanocomposite bilayers add another layer of tunability to the construct
related to cell adhesion in that the surface stiffness of the scaffold can be adjusted
with the number of bilayers coated on its surface. For example, freestanding films
of the same materials were shown to have increased Youngs modulus with increasing
numbers of bilayers [29]. The ability to tune mechanical properties and increase sur-
face stiffness by the addition of nanocomposite bilayers is important because substrate
mechanics have been shown to influence cell adhesion [15, 161, 162]. Additionally,
the bilayers provide a surface charge necessary for cell adhesion. Lastly, multilayer
films have also been shown to guide cell differentiation [163, 164]. In the framework
of this study, no difference in silicate and hydrogel ICC scaffold performance in terms
of bone marrow functionality was observed, although hydrogel scaffolds are preferred
due to much higher transparency and ease of confocal microscopy examination.
Self-renewal and maintenance of an undifferentiated population of CD34+ HSCs
and production of fully functional immune cells of specific leukocyte lineages are the
two basic functions of bone marrow most essential for applications mentioned above.
Bone marrow stroma is comprised of a complex reticulum containing hematopoietic
precursors, as well as non-hematopoietic cells such as fibroblasts, epithelial cells,
nerve cells, reticular cells, adipocytes and osteoid cells [147, 148, 152, 153, 163–165].
It is unknown how many or all of these cell types may be necessary to support
the development of fully functional leukocytes. Figs. 4.3 and 4.4 demonstrate the
successful expansion of CD34+ cells within the stromal-cell coated ICC scaffolds.
The direct interactions between stromal cells and CD34+ cells that can be seen in
Fig. 4.3) provided cues for the expansion of CD34+ cells rather than their quiescence
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or differentiation. Fig 4.4 demonstrates that the 3D ICC scaffolds induced much
greater CD34+ expansion than 2D plates.
The next step taken to demonstrate the functionality of the expanded CD34+ cells
was the production of B cells. Growth factors were added to the media to induce
differentiation. After seven days of culture (Fig 4.5) , the cells demonstrated nuclear
expression of RAG-1, which is a marker for immature B cells. By day 14, cells were
expressing IgM and CD19, which are B lymphocyte differentiation markers. By day
28, the co-expression of IgM and IgD indicated the presence of mature B cells. When
compared to 2D plates, a significantly greater percentage of cells in ICC scaffolds
displayed markers for CD40 and co-expression of IgM and IgD.
4.5 Conclusions
In this work we demonstrated the following key points. The use of 3D ICC cultures
allowed for significantly greater production of CD34+ cells when compared to 2D
cultures, demonstrating that dimensionality is a key component of the HSC niche.
Directed differentiation of the CD34+ cells also demonstrated that 3D culture in ICC
scaffolds produced greater expression of key B cell markers. ICC scaffolds allowed
for the growth, differentiation and movement of cells in a 3D environment effectively
mimicking the natural in vivo bone marrow environment normally encountered during
hematopoiesis and B lymphopoiesis.
4.6 Publications relevant to this chapter
The material in this chapter was performed in collaboration with the group of Dr.
Joan Nichols at the University of Texas Medical Branch. It is presented here with
minor modifications. The full study, which includes the stimulation of mature B cells
and in vivo studies, is found in following published article:
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Joan E. Nichols, Joaquin Cortiella, Jungwoo Lee, Jean A. Niles, Meghan Cud-
dihy, Shaopeng Wang, Joseph Bielitzki, Andrea Cantu, Ron Mlcak, Esther Valdivia,
Ryan Yancy, Matthew L. McClure, Nicholas A. Kotov. In vitro analog of human




Replication of Bone Marrow Differentiation Niche:
Comparison of Three-Dimensional Matrixes
5.1 Introduction
Many blood and bone marrow diseases, such as chronic myelogenous leukemia,
acute myelogenous leukemia, and bone marrow failure syndromes, are characterized
by disordered development or production of hematopoietic cells in the bone marrow
[166, 167]. The interactions between HSCs and the bone marrow niche are incredibly
complex and not completely understood [103, 146]. Bone marrow stroma, the tissue
surrounding hematopoietic tissue, is composed of a variety of cell types and ECM
molecules [151, 157, 168–170]. HSCs interact with these cell types directly through
cell-cell contacts or indirectly through secreted growth factors or ECM. In fact, some
of these HSC diseases are thought to be influenced by interactions with stromal cells
[171].
Despite the complexities of the HSC niche, current in vitro pre-clinical drug testing
methods are dependent on HSC culture on 2D surfaces. To provide niche signals to
the HSCs, they are cultured either on stromal cells [109, 110], in media supplemented
with high concentrations of growth factors [111, 112], or both. The 2D models allow
for the maintenance and expansion of HSC, but lack the dimensionality and ECM
components of the HSC niche [172]. With this in mind, 3D models of the bone marrow
niche, primarily designed for HSC expansion, were developed. These models ranged
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from nanofiber scaffolds [105, 108], to porous natural polymers [113] and synthetic
polymers [114, 115]. One of the most common 3D matrices used in hematopoietic and
other stem cell cultures is a commercially available matrix protein gel called Matrigel
[117, 118]. Matrigel is composed of extracellular matrix proteins extracted from
Engelbreth-Holm-Swarm mouse sarcomas. The gel has an advantage of being liquid
at 4 ◦C and gelling at 37 ◦C. With this property, Matrigel can be mixed with cells,
proteins, or other desired culture components at the low temperature, and plated or
injected into an animal where it will polymerize into a gel. As well, Matrigel contains
several growth factors, including transdermal growth factor (TGF)-beta, epidermal
growth factor, and fibroblast growth factor, so it can be a source of soluble signals
that may be useful for certain applications [24, 173–175]. As Matrigel is composed
of matrix from in vivo sources, cells can digest and restructure the matrix [83]. This
feature is useful for through-tissue migration studies [84], but can be hindering in
tissue engineering applications where matrix digestion disrupt the 3D structure. As
well, the murine source of Matrigel introduces the potential of viral contamination.
The batch-to-batch reproducibility of Matrigel is also a concern.
Recently, a 3D bone marrow analog was designed using ICC scaffolds [30]. ICC
scaffolds are hydrogel matrices with uniformly shaped spherical cavities arranged in a
hexagonal array where each cavity is connected to twelve adjacent cavities [12, 17, 26–
29, 31]. The bone marrow analog utilized a transparent acrylamide hydrogel with 70%
water content, coated with clay nanocomposite to allow for cell attachment and to
mimic the mineralized surface of bone. CD34+ cells, hematopoietic progenitor cells,
were expanded within scaffolds with the support of growth factors and bone marrow
aspirates, and the CD34+ cells were then differentiated into functioning B cells. The
results showed much greater expansion and directed differentiation of CD34+ cells
when compared to 2D cultures, demonstrating that the 3D interactions are necessary
for CD34+ cell expansion. The ICC scaffolds demonstrated some intrinsic advantages
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with the stromal-CD34+ cell co-culture. The geometry of closely-packed spherical
cavities provided 3D interactions between the stromal and stem cells. Physically,
the stem cells could contact stromal cells from multiple directions, especially when
compared to the unidirectional interactions on 2D well plates. As well, soluble factors
are released in all directions from the attached stromal cells, eliminating the steep
concentration gradient that is seen in 2D. The interconnectivity also played a large
role in stromal-stem cell interactions. As CD34+ cells are not attachment-based, they
were free to migrate throughout the scaffold. This is unique to the ICC scaffolds when
compared to encapsulation-based 3D matrices such as Matrigel.
An in vitro system that represents the interactions between HSCs and their niches
has great potential for use in pharmaceutical drug testing. In an in vitro HSC niche
for pharmaceutical drug testing, one would test drugs that specifically target bone
marrow, such as for anti-leukemia drugs, or those that have side effects within bone
marrow, like anti-virals [176]. Given that the in vitro niche accurately represents the
interactions within the in vivo HSC niche, the user could obtain information about
how the drug may act in the human body long before clinical trials. To learn about
the effects of drugs on HSCs and their niche, one should use cells as the source of
cytokines and other signals, rather than high doses added to the media. The choice
and number of stromal cells types should be highly controlled and simplified to make
the environment repeatable. Lastly, the environment should produce a stable number
of HSCs to best represent the body and to best see the effects of drugs on the system.
With these features in mind, we chose to compare three intrinsically different cell
culture formats: traditional 2D tissue cultured polystyrene, Matrigel, and ICC scaf-
folds. A direct comparison between these cell culture formats has not been published.
The three formats have great potential in bone marrow drug testing but have intrin-
sically have very different properties; thus, it is important to directly compare the
formats in the context of this potential. In addition to dimensionality and feature
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scale, it is important to note the differences in cell-cell contacts in each of these for-
mats. In 2D culture, the as CD34+ cells are plated on top of stromal cells so the two
cell types are in direct contact. In order to provide a true 3D structure to the Ma-
trigel culture, one must encapsulate the cell cultures in the gel by mixing the gel and
cells before plating. With cell encapsulation, cells are surrounded and separated by
matrix, limiting cell-cell contact. For cells to have cell-cell contact, they must digest
the matrix and migrate to one another. As ICC scaffolds have a porous 3D structure,
they can be seeded directly onto the matrix, allowing for them to contact not only
the matrix but also each other. Thus, with these three matrices we can compare
2D and 3D matrices, as well as those with intimate and limited cell-cell contact. As
well, we chose to examine HSC cultures with two stromal cell types. The first is the
HS-5 cell line, which secretes many HSC-supportive growth factors, as mentioned in
Chapter 4. The second is the hFOB 1.19 cell line, which has not been characterized
as well, but its known cellular products include alkaline phosphotase and osteocalcin
[145]. Osteoblasts are important to consider because of the extracellular matrix se-
creted and also because of osteoblast-HSC contacts that are known to be important
for HSC signalling, such as Ang1-Tie2 and transmembrane SCF [99, 103, 157]. In
vivo, bone marrow is a 3D tissue with extensive cell-cell contacts, so the distillation
of these features to those that are most important in a culture format and cellular
microenvironment is significant.
5.2 Materials and Methods
5.2.1 ICC fabrication
Colloidal crystals were prepared in a manner similar to those previously described
[25]. One gram of soda lime beads with a diameter of 80 µm (Thermo Scientific) were
mixed with approximately 5 mL of ethylene glycol. Under constant sonication, one
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drop of beads was added every 20 minutes to the top of the pipet that was inserted
into a 4.5 mm diameter vial. Drops were added until the height of beads in the vial
was approximately 1 centimeter (cm). Ethylene glycol was evaporated in a furnace
at 165 ◦C overnight, and beads were annealed at 665 ◦C for 3 h. Annealed colloidal
crystals were cracked out of the vials.
Cationic hydrogels were infiltrated and formed in the colloidal crystals as pre-
viously described [32]. Briefly, an initiator solution was made by adding 0.1 g
potassium persulfate (KPS) to 10 mL of deoxygenated water. Next, an acrylamide
precursor solution was made by adding 3.5 g N,N-dimethylacrylamide (DMAA),
0.5 g (3-Acrylamidopropyl)trimehtylammonium chloride (AMTAC), and 0.05 g N,N-
Methylenebis(acrylamide) (MBA) to 9 mL of deoxygenated water. Colloidal crystals
were added to vials, and enough precursor solution was added to completely sub-
merge the crystals. The colloidal crystals were then centrifuged in precursor solution
for 25 minutes at 5500 RPM. Next, 300 µL of initiator was added to each vial, and
centrifugation was repeated for an additional 15 minutes. Vials were heated in an
oven for 3 h at 75 ◦C with the caps placed on the vials but not screwed tight, and
then overnight at 60 ◦C with caps screwed tight. Gels were then cracked out of vials,
and excess gel was scraped off of the colloidal crystals using a razor blade.
Glass beads were removed as described previously using a series of HF and HCl
washes; removal of soda lime was accelerated by ultrasonicating during acid washes.
The resultant 1 cm ICCs were washed several times in PBS before cutting. To cut
the 1 cm ICCs into thin scaffolds, ICCs were first mounted in HistoGel (Thermo
Scientific), and cut into 350 µm thick sections using a Vibratome 3000 series sectioning
system (VIbratome, St. Louis, MO). Thin ICCs were then washed sequentially with
PBS, pH 10 buffer, calcium chloride, and PBS. Scaffolds were sterilized by washing
in 190 proof ethanol, and then were washed twice in sterile PBS.
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5.2.2 Stromal cell expansion
hFOB cell line 1.19 (CRL-11372) and bone marrow HS-5 cells (CRL-11882) were
purchased from ATCC (Manassas, VA). hFOB 1.19 cells were grown as recommended
by ATCC in 45% Hams F12 medium, 45% DMEM, and 10% FBS (Gibco, Frederick,
MD) supplemented with 0.3 mg/mL G418. HS-5 cells were grown as recommended by
ATCC in DMEM supplemented by 10% FBS and 1% penicillin-streptomycin. Both
cell types were grown at 37 ◦C and 5% CO2, with the medium changed every 2 to 3
days.
5.2.3 Stromal and CD34+ cell seeding in 2D cultures
For each matrix type, hFOB 1.19 or HS-5 cells were seeded at a density of 40,000
cells per culture. This number was chosen to avoid contact inhibition in 2D 96-well
plate cultures. Stromal cells were seeded directly onto the plate, and allowed to attach
for three hours before irradiating at 6000 rads. Media was then changed to StemSpan
(StemCell Technologies, Vancouver, BC) supplemented with 40 µg/mL low density
lipoprotein (Sigma) and 1% penicillin-streptomycin. Frozen bone marrow CD34+ cells
(StemCell Technologies) were thawed and washed with StemSpan as directed by the
cell supplier. CD34+ cells were added to cell cultures at a density of 10,000 cells/well
and cultured at 37 ◦C and 5% CO2. Controls were prepared by culturing CD34
+ cells
without stromal cells in 96-well plates.
5.2.4 Stromal and CD34+ cell seeding in Matrigel cultures
In order to encapsulate irradiated stromal cells with CD34+ cells in Matrigel,
hFOB 1.19 and HS-5 cells were irradiated at 6000 rads in 75 cm2 flasks prior to seeding
in gels. Matrigel cultures were prepared according to manufacturers instructions for
culturing cells within the matrix. Briefly, three tubes were placed on ice and equal
volumes of Matrigel was pipetted into each tube. hFOB 1.19 or HS-5 cells were
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counted and placed into Matrigel tubes so that each well would receive 40,000 stromal
cells; the third tube was left without cells. CD34+ cells were thawed and washed with
StemSpan, and CD34+ cells were added to cell cultures at a density so that 10,000
CD34+ cells would be included in each well. Matrigel, stromal cells, and CD34+ cells
were gently mixed by pipetting, and 32 µL of Matrigel-cell mixtures were added to
each well. Cells were cultured at 37 ◦C and 5% CO2.
5.2.5 Stromal and CD34+ cell seeding in ICC Scaffolds
One scaffold was placed in a well of a 96-well plate. 100 µL of 190 proof ethanol
was added to each well. Scaffolds were allowed to equilibrate for 10 minutes before
ethanol was removed and replaced with an additional 100 µL of fresh ethanol. After
10 minutes, most of the ethanol was removed and plates were placed in an incubator
at 37 ◦C overnight to evaporate any residual ethanol. The next day, cell solutions of
either hFOB 1.19 or HS-5 cells were made at a density of 40,000 cells per 20 µL .
20 µL of cell suspension gently was pipetted directly onto each dehydrated scaffold,
and well plates were placed in an incubator for three hours. Wells were then filled
halfway with HS-5 media (described above), and cells and scaffolds were irradiated
at 6000 rads. Media was then removed and replaced with StemSpan media. CD34+
cells were thawed and washed with StemSpan as described above. CD34+ cells were
added to cell cultures at a density of 10,000 cells/well and cultured at 37 ◦C and 5%
CO2. Controls were prepared by culturing CD34
+ cells without stromal cells in ICC
scaffolds.
5.2.6 Live/dead staining
After 8 days of culture, cells were incubated in 2 mM of calcein AM and 4mM
of ethidium homodimer-1 using a Live/Dead Viability/Cytotoxicity Kit (Invitrogen
Corporation, Carlsbad, CA). Images were acquired directly in 96-well plates using a
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Leica DM IRB inverted microscope.
5.2.7 Flow cytometric analysis
Enumeration of cells expressing the CD34+ marker was performed by flow cytom-
etry. For 2D and ICC cultures, cells were released through treatment with trypsin-
ethylenediaminetetraacetic acid (EDTA) and repeated pipetting. Matrigel cultures
were released by treatment with Dispase and repeated pipetting. Cells were washed
in ice cold 2% FBS in PBS, and incubated with fluorescently labeled CD34, gly-
cophorin A (GlyA), and lin1 (CD3, CD14, CD16, CD19, CD20, CD56) antibodies
(BD Biosciences, San Jose, CA). The combination of lin1 and GlyA are hereafter
referred to as lin. Relevant single color, negative, and isotype controls were prepared
for compensation and to distinguish specific binding. Flow cytometry was performed
on either a Beckman Coulter Quanta SC or a BD FCSCanto II. Regions positive for
CD34 and lin1/GlyA were determined based on isotype controls.
5.2.8 Enzyme-linked immunosorbent assay (ELISA)
ELISAs for IL-6 (R&D Systems, Minneapolis, MN), SCF (R&D Systems), and
fms-like tyrosine kinase receptor-3 (flt-3) (R&D Systems) were performed according
to manufacturer instructions.
5.2.9 Statistical Analysis
In all graphs, data is represented as the average of the indicated sample sizes ±




5.3.1 Imaging of cultures
Fig. 5.1 highlights the different cell-matrix interactions in each culture type. In
all culture formats, stromal-free cultures show a sparse number of rounded CD34+
cells and their progeny. These cultures showed little, if any, expansion. Of particular
interest are the cultures that included stromal cells. Figs 5.1B and C display 2D
cultures. Here, stromal cells lay flat and CD34+ cells and their progeny remain round
on top of the stromal cells. Stromal cells in Matrigel cultures (Fig 5.1E-F) are rounded
and isolated from the hematopoietic cells due to encapsulation. Some stromal cells
have migrated to the bottom of the plate and lay flat (Fig 5.1F). In ICC cultures
stromal cells are difficult to see because they conformably adhere to the matrix and
the hematopoietic cells cluster within cavities. Figs 5.1J-L display live/dead stains of
the matrices, further illustrating the cell morphologies and viability. In each culture,
cells appeared mostly viable.
5.3.2 Enumeration of cells within matrices
The number of cells that could be extracted from each culture type at days 7 and
14 were quantified using a hematocytometer (Fig 5.2A). These cells included both
stromal cells and CD34+ cells and their progeny. In all matrices the number of cells
in stromal cell-free culture were very low, indicating that these cells did not replicate
significantly. The cells extracted from 2D surfaces displayed little growth at day 7 but
had expanded by day 14. Conversely, cells grown in Matrigel expanded significantly
at day 7 but had decreased by day 14. ICC scaffold cultures displayed consistent
cell numbers over the two weeks. All co-cultures produced significantly (p<0.05)
more cells than the cultures with CD34+ cells alone. In all instances, within the
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Figure 5.1: Representative images of matrices. (A-I) Inverted microscope images of
cells in matrices on approximately day 7. (J-L) Confocal images with
live/dead stain. The first row of images (A, B, C) shows cells grown in
2D, the second row (D, E, F) shows cells grown in Matrigel, and the
third row (G, H, I) shows cells grown in ICC scaffolds. The first column
(A, D, G) displays CD34+ cells grown alone, the second column (B, E,
H) displays CD34+/hFOB 1.19 co-cultures, the third column (C, F, I)
displays CD34+/HS-5 co-cultures. The fourth row, cells stained with the
live/dead assay, shows cells grown in (J) 2D, (K) Matrigel, and (L) ICCs.
Green cells are alive, while cells stained red are dead. Scale bar: (A-I)
100 µm, (J-L) 80 µm.
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were not significantly different when compared to the HS-5 cultures. The amount
of expansion, represented as the number of cells extracted divided by the number of
cells initially seeded in the cultures, is displayed in Table 5-1.
Table 5.1: Expansion of cells in different matrices.
Total cells CD34+/lin- cells
Day 7 Day 14 Day 7 Day 14
2D CD34+ alone 0.42 0.02 0.14 0.01
hFOB 1.19 / CD34+ 0.99 8.57 0.24 0.85
HS-5 / CD34+ 1.02 6.23 0.38 1.05
Matrigel CD34+ alone 0.30 0.43 0.02 0.01
hFOB 1.19 / CD34+ 5.59 1.79 0.02 0.05
HS-5 / CD34+ 13.50 5.41 0.11 0.50
ICCs CD34+ alone 0.11 0.15 0.05 0.01
hFOB 1.19 / CD34+ 1.31 0.66 0.43 0.19
HS-5 / CD34+ 0.46 0.86 0.29 0.09
Expansion is calculated by the number of cells extracted divided by the number of
cells added to the matrix at the beginning of culture (total cells or CD34+/lin- cells).
5.3.3 Flow cytometric analysis
In most matrices stromal cell-free cultures displayed a higher percentage of cells
that were CD34+/lin- than the cultures with stromal cells (Fig 5.2B). It is important
to remember that these cultures began with 100% CD34+/lin- cells. In the majority of
co-cultures, the percentage of CD34+/lin- had decreased from 20% (as seeded) to less
than 10% of the total number of cells. For each matrix type, CD34+ cells cultured
alone displayed significantly (p<0.05) higher percentages of CD34+/lin- cells than
co-cultures of that same matrix type and day.
The number of CD34+/lin- cells (Fig 5.2C) was calculated by multiplying the
numbers shown in Fig 5.2A by those in Fig 5.2B. None of the matrices and cell
combinations significantly expanded the CD34+/lin- population (Table 5.1). 2D co-
cultures displayed a recovery of the original number of CD34+/lin- cells between 7 and
14 days. Matrigel, in contrast to Fig. 5.2A, produced very few CD34+/lin- cells by day
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Figure 5.2: Number and phenotype of cells extracted from cultures. (A) Number
of cells extracted from culture formats on indicated days. (B) Percent-
age of cells that displayed the CD34+/lin- phenotype. (C) Number of
CD34+/lin- cells extracted. (D) Representative dot plots of flow cytome-
try data for HS-5/CD34+ cultures in, from top to bottom, 2D, Matrigel,
and ICC cultures at seven days. Percentages on dot plots indicate the
percentange that measured CD34+/lin-; these cells are also indicated by
yellow dots.
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7, meaning that the expanded population seen in the first seven days was a progeny
population. ICC scaffolds displayed a fairly consistent number of CD34+/lin1- cells
from day 7 to day 14, though the original number had decreased largely by day 14. For
all matrices and times, co-cultures produced significantly (p<0.05) more CD34+/lin-
cells than CD34+ cells grown alone. When comparing co-cultures within culture
formats, at seven days, hFOB 1.19/CD34+ cultures in 2D produced significantly
more CD34+/lin cells than did HS-5/CD34+ cultures in 2D and at 14 days, for hFOB
1.19/CD34+ cultures in Matrigel produced significantly more CD34+/lin- cells than
did HS-5/CD34+ cultures in Matrigel. Comparing culture formats, 2D and ICC co-
cultures produced significantly more CD34+/lin- cells than Matrigel at seven days,
and at 14 days 2D cultures produced more CD34+/lin- cells all 3D matrices. Fig. 5.2D
displays representative CD34 versus lin1/GlyA dot plots for the three matrix types.
5.3.4 ELISAs
ELISAs for SCF, flt-3, and IL-6 were performed on media extracted from cultures
(Fig 5.3). SCF and flt-3 were found in concentrations much lower than cultures
used to expand HSCs [105]. Additionally, the concentrations did not vary between
cultures with and without stromal cells. IL-6 was found in concentrations 100 times
higher than flt-3 and IL-6. Stromal cell cultures had significantly higher levels of IL-6
than cultures without stromal cells. It appeared that HS-5 cells typically produced
significantly more IL-6 than hFOB 1.19 cultures.
5.4 Discussion
We chose three cell culture formats with very different architectures to explore the
contributions of dimensionality and cell-cell contacts to engineering an ex vivo HSC
niche. The traditional 96-well plate was a 2D culture that allowed for communication
through direct cell-cell interactions and secreted cytokines, Matrigel was a 3D culture
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Figure 5.3: Concentrations of relevant cytokines in the media as determined by
ELISAs. (A) SCF (B) Flt-3, (C) IL-6. Starred values represent val-
ues that are statistically significant (p<0.05) when compared to the other
stromal cell in that culture format (i.e., 2D, Matrigel, or ICC) for that
day (n = 6).
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that only allowed for communication via secreted cytokines, and ICC scaffolds rep-
resented 3D cultures that allow for communication via direct contacts and secreted
cytokines. Fig 5.1 demonstrates the diversity of geometries between these matrices.
2D cultures caused the stromal cells to lay flat on the plate surface, and HSCs typ-
ically associated with the top of these cells, rarely contacting the well plate, even if
a section was exposed. This was one indication that the CD34+ cells showed affinity
towards cell-cell contacts. Matrigel began with cells encapsulated through the ma-
trix. After one week, it was observed that the stromal cells had migrated toward the
bottom of the plate. ICC scaffolds allowed for direct 3D interactions between stromal
cells and CD34+ cells. It was observed that the CD34+ cells and their progeny ex-
panded in the cavities, as if they had formed their own niche. The geometry of ICC
scaffolds is much like that of trabecular bone; thus, the directionality of interactions
and degree of contact between stromal and stem cells is very similar in ICCs and bone
marrow. The cavities where the stem cell expansion was observed (Figs 5.1I and L)
are very similar to niches that are seen in the body.
It appeared that Matrigel caused differentiation and expansion, or vice versa, of
progeny over seven days. This is likely due to the dominance of cytokine signaling or
the lack of cell-cell contact. 2D cells produced the greatest number of CD34+ cells,
perhaps because 2D culture allowed for cytokine signaling and cell-cell contact. The
ICC culture, which allowed for both contact types in 3D, caused a fairly quiescent
population of cells between 7 and 14 days.
We looked into three of the signals that were secreted in the media, and found
that IL-6 was secreted at physiologically relevant levels, particularly by HS-5 cells.
Furthermore, we found that the pattern of IL-6 secretion in Fig 5.3C followed the
pattern of CD34+/lin- cell numbers in Fig 5.1C. Thus, it seemed that with the cell
types used here, particularly HS-5, IL-6 is the dominant secreted cytokine of those
tested. It is also interesting to note that although all three formats presented similar
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levels of IL-6, the 2D format showed the greatest expansion of CD34+/lin- cells. In
2D, there is a distinct concentration gradient from the source of soluble cytokines
at the bottom of the plate to the top of the plate. Therefore, in 2D cultures the
HSCs are exposed to very high concentrations of soluble cytokines. In 3D cultures,
this gradient is lessened considerably due to the arrangement of stromal cells, and
thus the secretion of soluble cytokines, in three dimensions. It is possible that the
concentration gradient of secreted cytokines could contribute to the quiescence or
expansion of the HSC.
The three cell culture formats allowed for the interaction of cell types by secreted
cytokines, though the two matrices that allowed for cell-cell contact did not show
the extensive differentiation and expansion seen in Matrigel cultures. It has been
hypothesized that the cell-cell contacts at the endosteal surface are important for stem
cell quiescence, particularly between HSCs and osteoblasts [99, 103, 157]. Thus, the
presence of HS-5 or hFOB 1.19 cells and the ability for HSCs to contact directly the
stromal cells may contribute to the data we see here. Additionally, the inclusion of 3D
cell-cell contacts may cause quiescence where it is not seen in 2D cultures (Fig 5.2C).
Studies have raised doubt in the importance of HSC-endosteal cell contacts [100, 177]
and suspected that the endosteal cell influence on HSC quiescence is due to secreted
cytokines, but we did not observe that in our in vitro cultures.
The data discussed here implies that direct cell-cell contacts are more important
than soluble cytokines for the quiescence of HSCs in the context of the osteoblasts
and bone marrow stromal cells used here. Additionally, it implies that 3D culture
further contributes to the quiescence of CD34+ cells. In vivo, the niche causes HSCs
to be quiescent [99], and the source of some HSC-derived cancers is in quiescent
stem cells [166, 167]. As the quiescent cancer stem cells are not affected by typical
chemotherapy drugs, the ability to keep HSCs quiescent in culture is essential in
a drug testing paradigm. When designing an in vitro HSC niche for the testing
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of drugs one should utilize a 3D matrix that allows for direct cell-cell contact and
secreted cytokine communication.
Of the two stromal cell types explored here, neither stood out in best recapitulating
the HSC niche by causing HSC quiescence. The specific receptors involved in the
contacts observed here need to be elucidated. It is likely that a combination of
several cell types may provide the cytokines and receptors necessary to provide the
signals that are necessary for an environment for drug testing. As well, the inclusion
of other cell types, such as endothelial cells that represent the sinusoidal vascular
niche [151, 178] may further contribute to mimicking the HSC niche.
5.5 Conclusions
The ability to organize key aspects of the HSC niche ex vivo will provide a tool for
studying pathology and potential cures for many blood and bone marrow diseases,
including chronic myelogenous leukemia and bone marrow failure diseases. Here,
we attempted to recreate the HSC niche while comparing several stromal cell types
and matrix types. Well plate cultures, which represent 2D formats, demonstrated
the greatest expansion of CD34+/lin- cells. These cultures provided permitted both
direct cell-cell contacts and soluble cytokine communication. Matrigel cultures, which
were 3D cultures where cell encapsulation inhibited cell-cell contacts but allowed for
communication through soluble cytokines, exhibited a large expansion of cells that
did not have the CD34+/lin- phenotype. ICC scaffolds, 3D cultures that permitted
both direct HSC-stromal cell contacts and the release of soluble cytokines, seemed
to cause quiescence of the CD34+/lin- cells, much like what is seen in in vivo bone
marrow.
The comparision of hFOB 1.19 and HS-5 stromal cells revealed that the dom-
inant soluble cytokine tested was IL-6. The presence of IL-6 correlated with the
production of CD34+/lin- cells. This was emphasized in 2D cultures, where the local
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concentration of soluble cytokines is higher near CD34+/lin- cells.
With this evidence, we conclude that 3D culture formats that provide direct cell-
cell contacts is essential in designing an ex vivo HSC niche. Realizing this is an
important step towards creating a niche that mimics the human body such that it
can be used for drug testing. In addition to the dimensionality of cell-cell contacts
and soluble cytokine gradients, one must also remember that the gradients of drugs,
as well as the ability of HSCs to be protected by stromal cells, is much closer to the
human body in 3D cultures. Further work needs to be done to elucidate the necessary
cell types that cause HSCs to behave as they do in the body. Once this is achieved,
the model should also be examined utilizing diseased HSCs, to ensure the model can
be used as a disease model. This will give clues to the pathophysiology of many blood
and bone marrow diseases.
5.6 Publications relevant to this chapter




Preliminary Drug Testing Experiments on
Inverted Colloidal Crystal Scaffold Hematopoietic
Stem Cell Niches
6.1 Introduction
Drug development for cancer and other diseases is a costly and time consuming
process, in part due to the necessity of screening thousands of compounds in order to
arrive at a few viable candidates. Worsening this inefficient process is the inability to
correctly screen out compounds using 2D culture systems, such as Petri dishes. As
well, animal tests are not always accurate, so failures are not recognized until human
clinical trials, which could be after up to a billion dollars of investment over almost
15 years [179].
The pharmaceutical industry, as well as drug discovery labs in academia and
biotech, lacks an effective early-stage and fairly inexpensive drug testing tool to pre-
dict a drugs behavior in the human body. It has been shown that many cell types,
such as breast epithelial cells [5, 180, 181], ovarian follicles [6, 182], pancreatic [183],
renal [184], display more complex cell-cell and cell-matrix interactions when grown
on 3D substrates than when on traditional widely used 2D plates or wells [185–187].
The paradigm-changing drug testing tool would be a 3D human cellular assay that
would allow drug testing on human cells organized in a tissue where cells can interact
as they would in the body. This is particularly important for many anticancer drugs
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that need to target 3D cell bodies/tumors rather than individual cells. In addition,
problems of drug transport, cell adaptation, and dormant cancers can be studied sub-
stantially more accurately within such a 3D cellular assay than in flat 2D cell systems
where dormant stage of cancer and collective cell behavior is difficult if not impossible
to realize.
Chronic myelogenous leukemia (CML) is diagnosed in approximately 5,000 people
a year in the U.S. In CML patients, the HSCs possess a mutated protein (bcr-abl)
that causes rapid cell division and an accumulation of myeloid cells in the marrow
and blood. Currently, a class of drugs that inhibit the bcr-abl protein, called tyrosine
kinase inhibitor (TKI)s, are available as treatments for CML. TKIs make the disease
manageable, but do not cure it. Resistance to TKIs is common as BCR-ABL, the
gene that codes for the bcr-abl protein, can mutate and interfere with TKI binding,
causing relapse [188]. It is thought that further developments in CML drugs will
focus on overcoming resistance to the available TKIs. With the development of new
classes of CML drugs in the next decade comes a need for new methods of in vitro
drug discovery and testing that might increase understanding of the disease and new
approaches to curing it. Current pre-clinical drug testing methods, which include
2D in vitro assays and in vivo transgenic mice, leave a gap in innovation as there
are no ex-vivo models that accurately represent the body. Traditional 2D cultures
neglect the 3D and complex multicellular aspects of in vivo HSC niches in bone
marrow. As CML is a disease originating from HSCs, one must take into account
the effect of the complex multicellular stem cell niche on the persistence of diseased
cells [104, 157, 169, 189–191]. Transgenic mouse models have been used extensively
[192, 193], but these animals are extremely expensive and do not always mimic the
human body. This leaves room for more advanced co-cultures or 3D methods to fully
understand the CML stem cell niche and utilize it in drug development.
For these reasons, we aim to develop a model of the HSC niche for drug testing.
77
In Chapter 5, we introduced the preliminary work in designing a niche using stromal
cells, HSCs, and comparing matrices. Due to the stability and quiescence of the HSCs
in ICC scaffolds, we chose to continue to look at these stromal cell/ICC combinations
within the context of drug testing. In our opinion, an ideal in vitro HSC niche for
drug testing should be as like the human body as possible, where the cells only receive
cues from other cells, via secreted matrix, soluble signals, and direct cell-cell contacts.
When adding a drug to a culture, it is impossible to know whether the reaction to
the drug is influenced by signals from high levels of exogenous cytokines. For this
reason, we chose to avoid exogenous cytokines in our cultures. In Chapter 5, we
looked at several stromal cells within matrices while looking at the replicative ability
of CD34+ cells. Here, we take a slightly different approach, in attempting to describe
the presence of hematopoietic lineages within the constructs. An ideal drug testing
tool utilizing the HSC niche should be simple to use, but it should also include the
many cell types that are found in bone marrow, including those that are derived from
HSCs.
As discussed in Chapter 5, the hFOB 1.19 and HS-5 cell types contribute differ-
ently to the HSC niche; thus, we continue here with several combinations of these
stromal cells within ICC to determine if a certain combination will cause the HSCs to
create a more marrow-like environment. We continue with looking at several stromal
cell combinations within the context of drug testing by adding several simple com-
pounds that should have a positive or negative effect on the cell cultures. The model
drugs that we chose were erythropoietin (EPO) and methotrexate (MTX). EPO is a
key growth factor involved in the regulation of erythropoiesis [192, 193]. Thus, with
the addition of EPO one would expect to see an upregulation of erythroid cell pro-
duction. Erythroid cell production has been documented at EPO concentrations as
low as 1 international units (IU)/mL, though the typical concentration in this context
are 3 IU/mL [194, 195]. MTX is a chemotherapy drug known to be cytotoxic to repli-
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cating cells by inhibiting DNA synthesis [196] [176]. We expected to see a decrease
in cell numbers in our models at a concentration of 10-6 M [197, 198]. These tests
are performed comparing 2D and ICC cultures. From here, we chose one stromal cell
type (hFOB 1.19), and cultured CD34+ cells within 2D and ICC cultures, adding two
different doses of EPO and MTX. We expected to see a more dramatic change in cell
number and type with increased drug dose.
6.2 Materials and Methods
6.2.1 ICC scaffold fabrication
ICCs were fabricated exactly as described in Chapter 5.
6.2.2 Stromal cell expansion
Stromal cells were expanded exactly as described in Chapter 5.
6.2.3 Stromal and CD34+ seeding in 2D and ICC cultures
In a first experiment, cells were seeded in ICC scaffolds in the following way.
One scaffold was placed in a well of a 96-well plate. 100 µL of 190 proof ethanol was
added to each well. Scaffolds were allowed to equilibrate for 10 min before ethanol was
removed and replaced with an additional 100 µL of fresh ethanol. After 10 min, most
of the ethanol was removed and plates were placed in an incubator at 37 ◦C overnight
to evaporate any residual ethanol. The next day, cell solutions of either hFOB 1.19,
HS-5 cells, or both, were made at a density of 40,000 cells per 20 µL. 20 µL of cell
suspension gently was pipetted directly onto each dehydrated scaffold, and well plates
were placed in an incubator for three hours. Wells were then filled halfway with HS-5
media and cells and scaffolds were irradiated at 6000 rads. Media was then removed
and replaced with StemSpan (StemCell Technologies, Vancouver, BC) media with
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40 µg/mL low density lipoprotein (Sigma) and 1% penicillin-streptomycin. CD34+
cells (StemCell Technologies) were thawed and washed with StemSpan as directed
by the cell supplier. CD34+ cells were added to cell cultures at a density of 10,000
cells/culture and cultured at 37 ◦C and 5% CO2. Controls were prepared by culturing
CD34+ cells without stromal cells in ICC scaffolds.
In the experiments that followed, ICC scaffolds were seeded in the same way, but
with only 1,000 CD34+ cells. 2D wells were seeded as follows. hFOB 1.19 or HS-5
cells were seeded at a density of 40,000 cells per culture. Stromal cells were seeded
directly onto the plate, and allowed to attach for three hours before irradiating at
6000 rads. Media was then changed to StemSpan supplemented with 40 µg/mL low
density lipoprotein (Sigma) and 1% penicillin-streptomycin. CD34+ cells were added
to cell cultures at a density of 10,000 cells/culture and cultured at 37 ◦C and 5%
CO2. Controls were prepared by culturing CD34
+ cells without stromal cells in the
96-well plate.
6.2.4 Cell extraction and enumeration
Cells in both 2D and ICCs were extracted in the same way. First, all media was
removed from cultures and set aside. Wells were rinsed briefly with approximately 20
µL of trypsin/EDTA, and the trypsin/EDTA were added to the media. Next, cells
were left in another 20 µL of trypsin/EDTA, and the trypsin/EDTA for approximately
10 minutes, until stromal cells were visibly detached. Liquid was removed and added
to the media; when removing liquid from ICC scaffolds, the liquid was pipetted several
times to dislodge any cells that may be in the center of the scaffold. Of the media and
trypsin that had been removed from each culture, 30 µL were set aside for counting
using a hemocytometer, and the rest was used in staining for flow cytometery.
80
6.2.5 Flow cytometric analysis
Cells were washed in ice cold 2% FBS in PBS, and incubated with a phycoery-
thrin (PE)-labeled antibody for CD34, and a FITC-conjugated antibody to GlyA,
a FITC-labeled antibody cockatil, lin1 (CD3, CD14, CD16, CD19, CD20, CD56),
and allophycocyanin (APC)-labeled antibodies to CD3, CD19, and CD56 (BD Bio-
sciences, San Jose, CA). With these labels, the CD34+ cells that are negative for
FITC or APC would be undifferentiated HSCs, the FITC+/APC- cells are lymphoid
cells, and the APC+/FITC- cells are myeloid cells. The combination of lin1 and GlyA
are hereafter referred to as lin. Relevant single color, negative, and isotype controls
were prepared for compensation and to distinguish specific binding. Flow cytometry
was performed on a BD FCSCanto II. Regions positive for CD34 and lin1/GlyA were
determined based on isotype controls.
6.2.6 ELISAs
ELISAs for IL-6 (R&D Systems, Minneapolis, MN), SCF (R&D Systems), and
flt-3 (R&D Systems) were performed according to manufacturer instructions.
6.2.7 Addition of drug
In each of the two experiments above, cells were cultured for three days, changing
75 µL media each day. On the third day of the first experiment, either EPO or MTX
was added. In the first experiment, 75 µL of media was replaced with media with
drug so that the entire volume of media per well (250 µL) would contained either 10-6
M MTX or 3 IU/mL EPO (Table 6.1). On each day thereafter, 75 µL of media with
drug was exchanged with fresh media with drug at the concentration of either 10-6 M
MTX or 3 IU/mL EPO. Control samples did not have any drug added.
In the second experiment, two doses of either EPO or MTX were added (Table
6.2). In the first experiment, 75 µL of media was replaced with media with drug
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so that the entire volume of media per well (250 µL) would contained either 10-6 M
MTX, 10-5 M MTX, 3 IU/mL, or 5 IU/mL EPO. On each day thereafter, 75 µL of
media with drug was exchanged with fresh media with drug at these concentrations.
Control samples did not have any drug added.
Table 6.1: Drug testing experiment 1: cell types and drug doses.
Drug and dose added
control EPO (IU/mL) MTX (M)
hFOB 1.19/CD34+ - 3 10-6
1:1 hFOB 1.19: HS-5/CD34+ - 3 10-6
HS-5/CD34+ - 3 10-6
Table 6.2: Drug testing experiment 2: drug doses.
Drug and dose added
control EPO (IU/mL) MTX (M)
Dose 1 - 3 10-6
Dose 2 - 5 10-5
6.2.8 Annexin/propidium iodide (PI) assay
In the second experiment, after one and seven days of adding drug cells were re-
moved as described in Section 6.2.4 and stained with the FITC Annexin V Apoptosis
Detection Kit I (BD Biosciences). Staining and flow cytometry was performed as de-
scribed by the manufacturer. Analysis was performed on a Beckman Coulter Quanta
SC flow cytometer.
6.2.9 Statistical Analysis
In all graphs, data is represented as the average of the indicated sample sizes
± standard deviation. A Student’s t-test was performed to determine statistical
significance. In graphs, significance (p<0.05) is indicated by a star.
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6.3 Results
6.3.1 Combinations of different stromal cells for the production of bone
marrow
The first set of experiments here explored different combinations of the hFOB 1.19
and HS-5 stromal cell types within ICC scaffolds to determine if a certain combina-
tion would best mimic the HSC niche. Fig 6.1 demonstrates the percentage and total
number of CD34+ cells that were extracted from the matrices. As well, the concen-
tration of IL-6 is displayed. Concentrations of SCF and flt-3 were also determined,
but there was no appreciable production of these growth factors (data not shown).
As seen in Chapter 5, the concentration of IL-6 was dependent on the presence of
at least 50% HS-5 cells. Still, at this point there was no data that gave an obvious
combination to be used in drug testing.
The next experiment utilized several combinations of stromal cells to determine
whether the stromal cells caused differentiation into the types of cells present in bone
marrow. Fig 6.2 displays the results for flow cytometric analysis of the different lineage
markers described above. Fig 6.2 demonstrates the presence of HSCs, myeloid cells,
and lymphoid cells. At day three of culture, 2D cultures showed a greater percentage
of cells that were of the myeloid lineage than ICC cultures.
6.3.2 Dosing experiment 1: Total cell enumeration and lineage presence
These experiments were continued in the context of drug testing. One dose each
of EPO and MTX were administered for up to seven days to co-cultures with com-
binations of hFOB 1.19, HS-5 and CD34+ cells. The results of enumerating the cells
that were extracted from 2D and ICC cultures are shown in Fig 6.3. None of the
cultures showed a change in cell number after one day of treatment, except for the
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Figure 6.1: Total cells extracted from cultures after seven and 14 days of culture.
(A) Percentage of cells positive for CD34 cell marker and negative for all
other markers. (B) Number of CD34+ cells as determined by multiplying
the percentage positive for CD34 and the total number of cells extracted
(data not shown). (C) Concentration of IL-6 growth factor as determined
by ELISA.
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Figure 6.2: Percentage of cells displaying various lineage markers. Each plot displays
two different culture formats: ICC scaffolds (1, 2, and 3), and 2D well
plates (4, 5, and 6). Each culture format was utilized for different stromal
cell combinations. Columns labeled 1 and 4 contained only hFOB 1.19
and CD34+ cells. Columns labeled 2 and 5 contained a 1:1 ratio of hFOB
1.19 and HS-5 cells and also CD34+ cells. Columns labeled 3 and 6
contained HS-5 cells and CD34+ cells. (A) Three days of culture. (B)
Ten days of culture.Starred values represent values that are statistically
significant (p<0.05) (n = 4).
EPO treatment, and the 1:0 hFOB 1.19:HS-5 cultures in ICCs treated with MTX,
which showed an increase in cell number with MTX treatment. Both of these were
the opposite of the predicted effects. In all three co-cultures, generally all cell cultures
increased in cell number after treatment with EPO for seven days. This is expected,
as EPO should promote the growth of myeloid cells. After seven days of treatment
with MTX, most cultures showed no significant change in cell number, but hFOB
1.19/HS-5 2D co-cultures (Fig 6.3E) showed an increase in cell number.
This data was elaborated by looking at the effects of the drugs on the specific
lineage types. The most interesting aspect of this data would be whether or not
myeloid cells were increased with the presence of EPO. After seven days of drug
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Figure 6.3: Total cells extracted from cultures after one and seven days of drug
treatment (Dosing experiment 1). (A-C) Treated with 3 IU/mL EPO.
(D-F) Treated with 10-6 M MTX. (A), (D) hFOB 1.19/CD34+ cultures.
(B),(E) 1:1 hFOB 1.19:HS-5/CD34+ cultures. C),(F) HS-5/CD34+ cul-
tures. Stars represent values that are statistically significant (p<0.05) (n
= 4).
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treatment, however, there was no difference between controls and treated cells in any
of the groups (Fig 6.4).
6.3.3 Dosing experiment 2: Total cell enumeration and lineage presence
The changes in cell number as a response to EPO were as expected in the hFOB
1.19 cultures above; thus, this cell type was used to test an increased dose of each drug.
In the second experiment, the doses in Table 6.2 were administered to co-cultures of
hFOB 1.19 and CD34+ cells. The results of enumeration of cells extracted from 2D
and ICC cultures are given in Fig 6.5. Here, one-day doses of EPO showed no change
in cell number (Fig 6.5A), and no trend after seven days (Fig 6.5C). Interestingly,
both 2D and ICC cultures showed a trend after one day towards less cells with MTX
treatment (Fig 6.5B). By seven days, both cultures were significantly limited by MTX
treatment (Fig 6.5C).
The lineages present in the cells in Fig 6.5 were examined via flow cytometry. The
data for EPO-treated cultures is presented in Fig 6.6. Between two and seven days
of drug treatment, the percentage of CD34+ increased for all groups. The predicted
increase in myeloid cell numbers was not seen with EPO treatment. In fact, all
myeloid cell percentages decreased over seven days. The data for the MTX-treated
drugs is presented in Fig 6.7. There is no difference between control and treated
groups.
6.3.4 Annexin/PI assay
The results of PI exclusion are given in Fig 6.8. No significant association by
annexin was shown (data not shown). It is likely that this is because for both days
the latest dose given was a day prior to the assay; thus, any apoptosis that may
have occurred at the time of adding the drug could not be measured at the time of
the assay. Figs 6.8A and C show little difference in cell death, as measured by PI
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Figure 6.4: Percentage of cells expressing lineage markers after extraction from cul-
tures after one and seven days of drug treatment (Dosing experiment 1).
(A-C) Two days of drug treatment. (D-F) Seven days of drug treatment.
(A), (D) Percentage CD34+/lineage-. (B), (E) Percentage positive for
lymphoid markers. (C), (F) Percentage positive for myeloid markers.
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Figure 6.5: Total cells extracted from cultures after one seven days of drug treatment
(Dosing experiment 2). (A), (C) Treated with EPO. (B),(D) Treated with
MTX. (A), (B) Results after one day of treatment with drug. (C), (D)
Results after seven days of drug exposure. Starred values represent those
that are statistically significant (p<0.05) (n = 4).
staining of DNA. In fact, of EPO-treated cultures, the only difference between treated
cultures and control cultures is seen in the 2D cultures on day 7 (Fig 6.8C), where
the EPO-treated cultures showed less cell death than controls. This means that EPO
does not cause cell death, as expected.
6.4 Discussion
We wished to explore the use of traditional well plate cultures and newer 3D
ICC cultures. In order to reduce any potential exogenous influences, we decided to
utilize stromal cells that are found in bone and bone marrow as a source of soluble
and insoluble signals, rather than adding growth factors to the media. As discussed
Chapter 5, osteoblasts and bone marrow stromal cells contribute uniquely to the
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Figure 6.6: Lineages present in EPO-treated cultures (Dosing experiment 2). (A-C)
Two days of drug treatment. (D-F) Seven days of drug treatment.(A), (D)
Percentage CD34+/lineage-. (B), (E) Percentage positive for lymphoid
markers. (C), (F) Percentage positive for myeloid markers.
cultures. As such, we decided to explore whether either of these cell types, or a
combination, represents the body in the context of drug testing by exhibiting the
responses to drugs that we expected.
Fig 6.1 confirms the data in Chapter 5 that the presence of HS-5 cells increases
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Figure 6.7: Lineages present in MTX-treated cultures (Dosing experiment 2). (A-
C) Two days of drug treatment. (D-F) Seven days of drug treatment.
(A), (D) Percentage CD34+/lineage-. (B), (E) Percentage positive for
lymphoid markers. (C), (F) Percentage positive for myeloid markers.
the secretion of IL-6, particularly at 7 days. Still, the number of stem cells present
did not vary with stromal cell type, meaning that each stromal cell type has unique
contributions to the cultures. In Fig 6.2, there was no trend indicating that a certain
lineage of cells was influenced by a specific stromal cell type. With this data, we could
not discern whether a single cell type could be chosen for drug testing uses. Thus, in
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Figure 6.8: PI exclusion assay (Dosing experiment 2). (A) Treated with 3 IU/mL
EPO. (C) Treated with 5 IU/mL EPO. (B) Treated with 10-6 M MTX.
(D) Treated with 10-5 MMTX. (A), (B) Results after one day of treatment
with drug. (C), (D) Results after seven days of drug exposure. Starred
values represent values that are statistically significant (p<0.05) (n = 4).
drug testing experiments we continued with a combination of stromal cells.
Fig 6.3 displays the data for dosing of these cell combinations with EPO and
MTX. Here, one can see that in hFOB 1.19/CD34+ cells, the response to seven days
of treatment with EPO is as predicted in both 2D and ICC cultures. HS-5/CD34+
and 1:1 hFOB 1.19:HS-5/CD34+ cultures treated with EPO were no different from
the control cultures. This is further confirmed in Fig 6.4, where there is not an
increase in the percentage of myeloid cells in EPO-treated cultures.
We expected cultures treated with MTX to show a decrease in the total number
of cells or inhibit production of cells. In Fig 6.3, one can see that hFOB 1.19/CD34+
cultures had no significant change in cell number when compared to control cultures.
The cells extracted from 1:1 hFOB 1.19:HS-5/CD34+ cultures in 2D increased with
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seven days of MTX exposure, which is the opposite result to what was expected.
HS-5/CD34+ cells displayed no difference when compared to controls.
As the results of the experiments in Fig 6.3 did not reveal any differences between
2D and ICC cultures or stromal cell combinations, we decided to look into whether
increased concentrations of these drugs would elicit a more obvious response. We
chose to utilize hFOB 1.19 cells because of their ease of expansion and appropriate
response to EPO treatment in Fig 6.3.
Fig 6.5 displays the results of treating hFOB 1.19/CD34+ cultures with the drugs
and doses in Table 6.2. Again, EPO did not cause significant increases in cell num-
bers. MTX cultures showed the expected response of a decrease in cell numbers in
both 2D and ICC cultures after seven days of treatment; however, there were not
further decreases in cell number with increased MTX dose. It should be noted that
the number of cells in the MTX-treated cultures remained similar when comparing
Fig 6.3 and Fig 6.5, but the number of control cells increased significantly in Fig 6.5.
Thus, the experiment should be replicated to determine whether the responses are
repeatable.
The percentage of extracted cells that were labeled as dead is displayed in Fig 6.8.
Figs 6.8A and C show the percentage of dead cells in EPO cultures. It should be noted
that there is some cell death upon the inoculation of CD34+ cultures; CD34+ have
approximately 80% viability upon arrival. As well, stromal cell cultures naturally
have some cell death with irradiation and aging of cells. There is a decrease in the
percentage of dead cells between days 1 and 7. This can be explained by the overall
increase in cell numbers (Fig 6.5), indicating that the CD34+ or their progeny had
expanded. In summary, EPO treatment did not cause any significant cell death in
any cultures or doses.
Figs 6.8B and D display the percentage of dead cells after MTX treatment. There
is more cell death observed in MTX-treated cultures than in control cultures. This
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confirms the data seen in Fig 6.5 where less cells were observed in MTX-treated
cultures. In fact, the decrease in cell numbers is not only due to the lack of cell
replication, but due to increased cell death, meaning the MTX treatment causes
more cell death than control cultures.
The cultures did not show increased response to increased doses of either drug.
With respect to EPO treatment, as the hormone regulates erythrocyte production,
we would expect to see an increase in cell number. However, many growth factors
are involved in the up-regulation of erythroid cell production [194, 199]. As this is
a simple model with only two cell types, some of the necessary growth factors, such
as SCF are not present (Chapter 5). In future experiments, a chemical should be
chosen that up-regulates the production of a hematopoietic cell type without working
in cooperation with another growth factor. As well, the model needs to be adjusted
to include additional cell types that make the model more physiologically relevant.
6.5 Conclusions
The creation of an in vitro method of drug testing could revolutionize the phar-
maceutical industry, allowing companies to collect information about how the drug
will act in the body long before it is introduced into human clinical trials. As well,
such a collection of assays could significantly reduce the amount of animal testing in
the industry.
Here, we looked at two culture formats, 2D well plates and 3D ICC scaffolds, as
well as different stromal cell types. Varying stromal cell types did not show significant
differences in drug response, though this deserves greater exploration as stromal cells
contribute to disease and drug response. Similar responses were seen in both 2D
and 3D cultures. This is encouraging, in that the simplistic mechanisms of EPO and
MTX may not be affected by dimensionality. Future work with drugs that are used
to specifically treat CD34+ cells, such as those that are used against CML, may show
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more significant responses when looking at stromal cells or dimensionality due to the
affects of stromal cells on disease pathology.
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CHAPTER VII
Summary and Future Directions
7.1 Summary
ICC scaffolds have great potential in the applications of tissue engineering for
several reasons. First, the unique and highly controllable structure allows one to
control the size of cavities and interconnecting channels, affording the possibility of
studying the effects of feature size on such characteristics as cell seeding and migra-
tion, diffusion of drugs and other molecules, and mechanical properties. As well, ICC
scaffolds can be fabricated out of any material that can be made into a liquid and
later solidified or gelled. One can also image cells directly within hydrogel scaffolds.
This dissertation presented work utilizing ICC scaffolds within the context of
bone and bone marrow engineering. The first part of this dissertation presented
the first work to create this structure out of a biodegradable polymer. Here, we
demonstrated microscale control over cavity and interconnecting channel sizes, and
that the mechanical properties were higher than scaffolds with stochastic structures.
The scaffolds were also shown to be biocompatible. Next, the structure was fabricated
out of polyacrylamide hydrogel, which was used to grow a HSC niche that supported
HSC expansion and directed differentiation. The scaffolds were further explored for
HSC engineering in a study that compared the scaffolds to Matrigel and 2D cultures.
This demonstrated that ICC scaffolds provided an environment where HSCs remained
quiescent, similar to the human body. Last, this dissertation presented initial work
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in utilizing the matrices for drug testing.
7.1.1 Bone tissue engineering
The ultimate goal of bone tissue engineering is to design implantable scaffolds to
promote and guide bone growth into a wound site. Ideally, the scaffold should degrade
at the same rate that bone grows into the scaffold. With this design, eventually the
wound site will be filled with healthy bone. The material chosen for the ICC scaffolds
discussed here was PLGA, which is a well-characterized biodegradable polymer that
hydrolytically degrades over months in the body into lactic acid and glycolic acid,
which are naturally found in the human body [200, 201].
In order to facilitate bone and vasculature ingrowth, cell and/or cytokine seeding,
and nutrient and waste diffusion, the scaffolds must be porous. As well, the scaffold
geometry should be completely interconnected, meaning that there are no areas of
the scaffold that are isolated, so that the scaffold is a consistent growth environment
and also so that tissue grows in evenly. A major problem with traditional scaffold
design, which imparts random porosity into the bulk material, is that the scaffolds
must have high porosities, as high as 95%, to ensure complete connectivity. With
such high porosities, the mechanical properties of the bulk material are sacrificed.
Due to the ordered structure of ICC scaffolds, ICCs have complete interconnectivity
at porosities as low as 63-74% [63, 121]. In Chapter 3, we demonstrated that the
scaffolds have compressive moduli that are much greater than typical scaffolds with
a stochastic pore geometry.
In addition to the mechanical property advantages of the highly ordered structure
of ICC scaffolds, we demonstrated that their fabrication methods allowed for control
over several microscale properties of the scaffolds. The cavity diameter could be
controlled by changing the diameter of the beads used as a CC template; this was
demonstrated with beads with diameters of 100, 200, and 330 µm. Additionally, by
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changing the annealing temperature of the beads, we showed that the interconnecting
channel diameter can be controlled. At the time that these scaffolds were developed,
there was no other way to obtain precise control on a scale as low as 30 µm. More
recently, SFF-based fabrication methods have improved to provide control on a similar
or better scale [61].
7.1.2 Bone marrow engineering
Next, the dissertation focused on the use of the ICC scaffolds to create hydrogel
structures for bone marrow engineering. In contrast to the PLGA scaffolds, here the
goal was to create a stable environment mimicking the HSC niche, with the ultimate
application to be in pharmaceutical drug testing. A nonbiodegradable hydrogel was
chosen so that the matrix environment would not change over time. The matrix was
seeded with stromal cells, and without exogenous cyokines was able to support the
expansion of CD34+ HSCs for up to 28 days while being cultured in a rotary reactor.
In comparison to 2D plates, ICC scaffolds produced approximately twice the percent-
age of cells that were CD34+. As well, loss of CFSE showed that CD34+ cells in ICCs
replicated approximately 10 times more than those in 2D plates. These data together
demonstrate that the expansion of CD34+ HSCs was much greater in ICC scaffolds
than in 2D plates. The identity of the CD34+ cells was confirmed through flow cy-
tometry and the ability to direct the lineage of differentiation HSC. The addition of
cytokines to cause the differentiation of the CD34+ cells into B-cells resulted in sur-
face expression of markers characteristic of B-cells. Markers were several times more
frequent in ICCs than in 2D plates. This was functionally characterized by exposing
cells to lipopolysaccharide, which stimulated the production of IgM, demonstrating
that the cells produced from CD34+ cells functioned as B-cells. Concentrations of
IgM in media were 10-20 times higher in ICCs. The data presented here demon-
strated that the contacts presented by 3D cultures were important in HSC expansion
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and retention of function.
The ultimate goal of the bone marrow engineering described here is to apply the
matrices for ex vivo drug testing. With this in mind, we wished to simplify the use
of the matrix so that it could be used in a drug testing format. The next project
utilized the ICC scaffolds within 96-well plates, and compared it to the traditional 96-
well plate cultures and a well-known commercially available matrix, Matrigel. Here,
several stromal cells were compared to determine if the HSC niche could be replicated
with just one stromal cell type. It was found that the 2D 96-well plate caused the
greatest expansion of CD34+ cells over 14 days. This is likely due to signals both
released into the media and also from cell-cell contacts. Matrigel, which inhibited
cell-cell contacts, had a great degree of total cell expansion, but a low percentage
of CD34+ over 14 days. It was suspected that this is due to the lack of direct cell-
cell contacts. ICC scaffold cultures demonstrated little change in the number of
CD34+ cells over 14 days. This behavior is observed in human bone marrow, and is
described as HSC quiescence. The quiescence seen in ICC scaffolds were thought to
be because the matrix provided soluble and direct cell-cell communication, and also
provided contacts in 3D, much like the structure of human bone marrow. The 3D
communication minimizes gradients of soluble signals, and allows for HSC-stromal
cell contact with directionality, much like contacts in the body.
The last section utilized the ICC scaffolds in the context of drug testing. Here,
stromal cell-HSC cultures were performed in 2D 96-well plates and in ICC scaffolds.
The cultures were treated with model drugs, EPO and MTX at several doses. It
was found that there was an expected response of decreased cell number with MTX
treatment, but no significant increase in cell number with EPO treatment.
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7.2 Future directions in bone tissue engineering
This work presented here on PLGA ICC scaffolds was the first step in a larger
project of multiscale bone tissue engineering. Here, we demonstrated control on the
micro-scale by varying the cavity and interconnecting channel size. In particular,
there are several ways to impart macro- and nano-scale control on the ICC scaffolds
discussed here.
7.2.1 Macro-scale control
As mentioned above, a major consideration in bone scaffold engineering is to en-
sure sufficient permeability of nutrients and waste, as well as space for vasculature
ingrowth. SFF fabrication-based techniques could be combined with the ICC struc-
tures to create the ordered and controllable structure over a larger scale (Fig 7.1).
The macro-scale design of the SFF fabricated matrices could be designed to ensure
the matrices have high mechanical properties and sufficient pore space for nutrient
and waste diffusion. As well, the scaffolds should have sufficient space for bone and
vasculature ingrowth. The micro-scale porosity donated to the scaffold structure by
the ICC geometry will increase the surface area of the scaffolds for greater cell at-
tachment. Lastly, the implantation of the scaffolds into an animal model could reveal
further clues as to the ideal pore size to facilitate bone and vasculature growth into
the scaffolds.
7.2.2 Nano-scale control
One of the most important future directions of bone tissue engineering is to fur-
ther control the structure of scaffolds on a smaller scale, and to integrate this control
into the micro-scale. Bone is composed of collagen fibrils and nanostructured HA, so
the inclusion of calcium phosphate nanoparticles may improve the mechanical prop-
erties of the bulk polymer. As well, the precise arrangement of the nanoparticles may
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Figure 7.1: Micro-computed tomography images of CCs in a crossbar arrangements.
CCs were fabricated by depositing glass beads under sonication into a
mold fabricated by SFF techniques. Beads were annealed, and the mold
was subsequently dissolved.
increase these mechanical properties. Currently, the Kotov group is attempting to
construct a 3D structure out of nano-structured calcium phosphate [202] and a poly-
mer (e.g., PDDA) via LBL synthesis. In addition to potential increases in mechanical
properties, the inclusion of nano-structured materials can impart nano-sized surface
properties. As cells have been shown to attach to nano-structured surfaces, these
properties can aid the attachment and migration of cells within the matrix.
7.3 Future directions in bone marrow engineering
7.3.1 Choice of cell types in bone marrow engineering
The concept of bone marrow engineering for drug testing is new and not thor-
oughly explored. One complexity in this task is the balance of functionality and
simplicity of the model. As discussed in Chapter 2, bone marrow is an incredibly
complex environment of many cell types that contribute to the fate of HSCs through
direct cell-cell contacts, ECM production, and soluble cytokine production. To fully
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recapitulate bone marrow, an ex vivo model should incorporate all cell types in the
proper ratios to produce signals that properly mimic those in the body. To make
this model practical and reproducible, however, calls for simplicity in the number of
cell types included in the model. Distilling the bone marrow microenvironment to
several key components will be a difficult task. In addition to the bone and stromal
cells explored in this dissertation, endothelial cells and adipocytes may be necessary
to provide the most realistic cellular environment.
It is necessary to explore bone marrow models that utilize cells that represent
a disease. Most importantly, the inclusion of primary disease cells, such as those
extracted from the bone marrow of a CML patient, could provide clues about how
cells interact with stromal cells, the pathology of the disease, or how cells react to
certain drugs. As well, cell lines could be included. K-562, HL60, and Kasumi-6
are cell lines that mimic leukemias [203]. Comparing the replication, function, and
reaction of these cell lines to chemotherapeutic drugs in 3D and 2D environments
could provide basic information about the pathology of leukemias.
7.3.2 Choice of drugs used to validate the model
The models discussed in Chapter 6 did not demonstrate a difference between
2D and 3D cultures in the context of drug testing. Once the cell types have been
deemed appropriate to mimic human bone marrow, different classes of drugs should
be explored, including those that directly affect bone marrow, such as anti-virals.
A wide range of drug concentrations should be explored to elucidate whether one
culture exhibits greater sensitivity due to diffusion or arrangement of cells within the
microenvironment.
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7.4 Future directions in ICC scaffold development
7.4.1 Cell extraction from hydrogel ICC scaffolds
There are several developments that could be improved in the ICC scaffolds them-
selves. The most important issue that was observed through the course of this disser-
tation work is the extraction of cells from the scaffold for counting or flow cytometric
analysis. Some 3D matrices, such as Matrigel, are composed of a material that de-
grades when exposed to the enzyme dispase. This allows for ease of removal of cells
that are in the center of the matrix. The current polyacrylamide ICC scaffolds cannot
be degraded, so all cells must be removed from the scaffold via repeated pipetting.
As the scaffold geometry is tortuous, it is difficult to extract cells from the center
of the matrix. An ideal improvement to the scaffold would be to include chemistry
within the polymer that could cause degradation of the scaffold upon the addition of
an enzyme or a cellularly benign chemical.
7.4.2 Assay development
An ideal scaffold for drug testing would be integrated with current assays and
instrumentation. Current assays and protocols are developed for use with 2D cell
cultures. In these, the reagents are added to the 2D cultures, and the cultures ana-
lyzed directly using a microplate reader. To fully take advantage of the transparent
hydrogel ICCs, it should be explored whether current assays can be performed di-
rectly within ICC scaffolds. This would greatly add to the value of the scaffolds and
their ease of use.
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[94] P Q Ruhé, E L Hedberg-Dirk, N T Padron, P H M Spauwen, J A Jansen, and
A G Mikos. Porous poly(dl-lactic-co-glycolic acid)/calcium phosphate cement
composite for reconstruction of bone defects. Tissue Eng, 12(4):789–800, 2006.
[95] F Zhao, W L Grayson, T Ma, B Bunnell, and W W Lu. Effects of hydroxyap-
atite in 3-d chitosan-gelatin polymer network on human mesenchymal stem cell
construct development. Biomaterials, 27(9):1859–67, 2006.
[96] K G Marra, J W Szem, P N Kumta, P A DiMilla, and L E Weiss. In vitro
analysis of biodegradable polymer blend/hydroxyapatite composites for bone
tissue engineering. J Biomed Mater Res, 47(3):324–35, 1999.
[97] S-S Kim, M S Park, O J, C Y Choi, and B-S Kim. Poly(lactide-co-
glycolide)/hydroxyapatite composite scaffolds for bone tissue engineering. Bio-
materials, 27(8):1399–409, 2006.
[98] G B Adams, K T Chabner, I R Alley, D P Olson, Z M Szczepiorkowski,
M C Poznansky, Claudine H Kos, Martin R Pollak, Edward M Brown, and
David T Scadden. Stem cell engraftment at the endosteal niche is specified by
the calcium-sensing receptor. Nature, 439(7076):599–603, 2006.
[99] F Arai, A Hirao, M Ohmura, H Sato, S Matsuoka, K Takubo, K Ito, G Y Koh,
and T Suda. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell
quiescence in the bone marrow niche. Cell, 118(2):149–61, 2004.
[100] M J Kiel and S J Morrison. Uncertainty in the niches that maintain haematopoi-
etic stem cells. Nat Rev Immunol, 8(4):290–301, 2008.
111
[101] R S Taichman and S G Emerson. The role of osteoblasts in the hematopoietic
microenvironment. Stem Cells, 16(1):7–15, Jan 1998.
[102] T Sugiyama, H Kohara, M Noda, and T Nagasawa. Maintenance of the
hematopoietic stem cell pool by cxcl12-cxcr4 chemokine signaling in bone mar-
row stromal cell niches. Immunity, 25(6):977–88, 2006.
[103] G B Adams and D T Scadden. The hematopoietic stem cell in its place. Nat
Immunol, 7(4):333–7, 2006.
[104] D T Scadden. The stem-cell niche as an entity of action. Nature,
441(7097):1075–9, 2006.
[105] K-N Chua, C Chai, P-C Lee, S Ramakrishna, K W Leong, and H-Q Mao.
Functional nanofiber scaffolds with different spacers modulate adhesion and
expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor
cells. Exp Hematol, 35(5):771–81, 2007.
[106] M R Doran, B D Markway, I A Aird, A S Rowlands, P A George, L K Nielsen,
and J J Cooper-White. Surface-bound stem cell factor and the promotion of
hematopoietic cell expansion. Biomaterials, 30(25):4047–52, 2009.
[107] L Hou, T Liu, J Tan, W Meng, L Deng, H Yu, X Zou, and Y Wang. Long-term
culture of leukemic bone marrow primary cells in biomimetic osteoblast niche.
Int J Hematol, 90(3):281–91, 2009.
[108] K Ma, C K Chan, S Liao, W Y K Hwang, Q Feng, and S Ramakrishna. Elec-
trospun nanofiber scaffolds for rapid and rich capture of bone marrow-derived
hematopoietic stem cells. Biomaterials, 29(13):2096–103, 2008.
[109] B A Roecklein and B Torok-Storb. Functionally distinct human marrow stromal
cell lines immortalized by transduction with the human papilloma virus e6/e7
genes. Blood, 85(4):997–1005, 1995.
[110] B A Roecklein, J Reems, S Rowley, and B Torok-Storb. Ex vivo expansion
of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from g-
csf-mobilized peripheral blood. Biol Blood Marrow Transplant, 4(2):61–8, 1998.
[111] C Rofani, L Luchetti, G Testa, R Lasorella, G Isacchi, G F Bottazzo, and
A C Berardi. Il-16 can synergize with early acting cytokines to expand ex vivo
cd34+isolated from cord blood. Stem Cells Dev, 18(4):671–682, 2009.
[112] P W Zandstra, E Conneally, A L Petzer, J M Piret, and C J Eaves. Cytokine
manipulation of primitive human hematopoietic cell self-renewal. Proc Natl
Acad Sci USA, 94(9):4698–703, 1997.
[113] C H Cho, J F Eliason, and H W T Matthew. Application of porous
glycosaminoglycan-based scaffolds for expansion of human cord blood stem cells
in perfusion culture. J Biomed Mater Res A, 86(1):98–107, 2008.
112
[114] Q Feng, C Chai, X-S Jiang, K W Leong, and H-Q Mao. Expansion of engrafting
human hematopoietic stem/progenitor cells in three-dimensional scaffolds with
surface-immobilized fibronectin. J Biomed Mater Res A, 78(4):781–91, 2006.
[115] Y Li, T Ma, D A Kniss, S T Yang, and L C Lasky. Human cord cell
hematopoiesis in three-dimensional nonwoven fibrous matrices: in vitro simula-
tion of the marrow microenvironment. J Hematother Stem Cell Res, 10(3):355–
68, 2001.
[116] G Mehta, M J Kiel, J W Lee, N A Kotov, J J Linderman, and S Takayama.
Polyelectrolyte-clay-protein layer films on microfluidic pdms bioreactor surfaces
for primary murine bone marrow culture. Adv Funct Mater, 17:2701–2709, 2007.
[117] K Chadwick, LWang, L Li, P Menendez, B Murdoch, A Rouleau, and M Bhatia.
Cytokines and bmp-4 promote hematopoietic differentiation of human embry-
onic stem cells. Blood, 102(3):906–15, 2003.
[118] B Heissig, K Hattori, S Dias, M Friedrich, B Ferris, Neil R Hackett, R G Crystal,
P Besmer, D Lyden, M A S Moore, Z Werb, and S Rafii. Recruitment of stem
and progenitor cells from the bone marrow niche requires mmp-9 mediated
release of kit-ligand. Cell, 109(5):625–37, 2002.
[119] X Liu and P Ma. Polymeric scaffolds for bone tissue engineering. Ann Biomed
Eng, 32(3):477–486, 2004.
[120] Y S Nam and T G Park. Porous biodegradable polymeric scaffolds prepared
by thermally induced phase separation. J Biomed Mater Res, 47(1):8–17, Oct
1999.
[121] C Song, P Wang, and H A Makse. A phase diagram for jammed matter. Nature,
453:629–632, 2008.
[122] E Jan and N Kotov. Successful differentiation of mouse neural stem cells on
layer-by-layer assembled single-walled carbon nanotube composite. Nano Lett,
7(5):1123–1128, 2007.
[123] S Manolagas, D Burton, and L Deftos. 1, 25-dihydroxyvitamin d3 stimulates
the alkaline phosphatase activity of osteoblast-like cells. Journal of Biological
Chemistry, 256(14):7115–7, 1981.
[124] M Gomes, H Holtorf, R Reis, and A Mikos. Influence of the porosity of starch-
based fiber mesh scaffolds on the proliferation and osteogenic differentiation of
bone marrow stromal cells cultured in a flow perfusion bioreactor. Tissue Eng,
12(4):801–9, 2006.
[125] H Holtorf, N Datta, and J Jansen. Scaffold mesh size affects the osteoblas-
tic differentiation of seeded marrow stromal cells cultured in a flow perfusion
bioreactor. J Biomed Mater Res A, 74(2):171–80, 2005.
113
[126] L Mathieu, T Mueller, P Bourban, and D Pioletti. Architecture and prop-
erties of anisotropic polymer composite scaffolds for bone tissue engineering.
Biomaterials, 27(6):905–16, 2006.
[127] Y Cao, G Mitchell, A Messina, L Price, and E Thompson. The influence
of architecture on degradation and tissue ingrowth into three-dimensional poly
(lactic-co-glycolic acid) scaffolds in vitro and in vivo. Biomaterials, 27(14):2854–
64, 2006.
[128] V Chen and P Ma. The effect of surface area on the degradation rate of nano-
fibrous poly (l-lactic acid) foams. Biomaterials, 27(20):3708–15, 2006.
[129] V Karageorgiou and D Kaplan. Porosity of 3d biomaterial scaffolds and osteo-
genesis. Biomaterials, 26(27):5474–91, 2005.
[130] J Zeltinger, J Sherwood, and D Graham. Effect of pore size and void fraction on
cellular adhesion, proliferation, and matrix deposition. Tissue Eng, 7(5):557–72,
2001.
[131] S Hulbert, F Young, and R Mathews. Potential of ceramic materials as per-
manently implantable skeletal prostheses. J Biomed Mater Res A, 4(3):433–56,
1970.
[132] F Klenke, Y Liu, and H Yuan. Impact of pore size on the vascularization and
osseointegration of ceramic bone substitutes in vivo. J Biomed Mater Res A,
85(3):777–86, 2008.
[133] A Itala, H Ylanen, C Ekholm, and K Karlsson. Pore diameter of more than
100 micro m is not requisite for bone ingrowth in rabbits. J Biomed Mater Res
A, 58(6):679–83, 2001.
[134] B Flautre, M Descamps, C Delecourt, and M Blary. Porous ha ceramic for bone
replacement: Role of the pores and interconnections–experimental study in the
rabbit. J Mater Sci Mater Med, 12(8):679–82, 2001.
[135] Y Kuboki, Q Jin, and H Takita. Geometry of carriers controlling phenotypic
expression in bmp-induced osteogenesis and chondrogenesis. J Bone Joint Surg
Am, 83-A Suppl 1(Pt2):S105–15, 2001.
[136] Y Kuboki, Q Jin, and M Kikuchi. Geometry of artificial ecm: sizes of pores con-
trolling phenotype expression in bmp-induced osteogenesis and chondrogenesis.
Connective tissue research, 43(2-3):529–34, 2002.
[137] O Zinger, G Zhao, Z Schwartz, J Simpson, and M Wieland. Differential
regulation of osteoblasts by substrate microstructural features. Biomaterials,
26(14):1837–47, 2005.
[138] S Goldstein. Tissue engineering. Ann NY Acad Sci, 961(Reparative
Medicine):183–192, 2006.
114
[139] P Ma and J Choi. Biodegradable polymer scaffolds with well-defined intercon-
nected spherical pore network. Tissue Eng, 7(1):23–33, 2001.
[140] L Shea, D Wang, and R Franceschi. Engineered bone development from a
pre-osteoblast cell line on three-dimensional scaffolds. Tissue Eng, 6(6):605–17,
2000.
[141] M Mondrinos, R Dembzynski, L Lu, and V Byrapogu. Porogen-based solid
freeform fabrication of polycaprolactone-calcium phosphate scaffolds for tissue
engineering. Biomaterials, 27(25):4399–408, 2006.
[142] T Hildebrand, A Laib, and R Müller. Direct three-dimensional morphometric
analysis of human cancellous bone: microstructural data from spine, femur,
iliac crest, and calcaneus. J Bone Miner Res, 14(7):1167–74, 1999.
[143] M Kang, W Lee, K Oh, J Han, K Song, and B Cha. The short-term changes
of bone mineral metabolism following bone marrow transplantation. Bone,
26(3):275–9, 2000.
[144] H Wang, Y Li, Y Zuo, J Li, S Ma, and L Cheng. Biocompatibility and osteo-
genesis of biomimetic nano-hydroxyapatite/polyamide composite scaffolds for
bone tissue engineering. Biomaterials, 28(22):3338–48, 2007.
[145] S A Harris, R J Enger, B L Riggs, and T C Spelsberg. Development and
characterization of a conditionally immortalized human fetal osteoblastic cell
line. J Bone Miner Res, 10(2):178–86, 1995.
[146] A Wilson and A Trumpp. Bone-marrow haematopoietic-stem-cell niches. Nat
Rev Immunol, 6(2):93–106, 2006.
[147] J Barker and C M Verfaillie. A novel in vitro model of early human adult
b lymphopoiesis that allows proliferation of pro-b cells and differentiation to
mature b lymphocytes. Leukemia, 14(9):1614–20, 2000.
[148] J Chen, J S Brandt, F M Ellison, R T Calado, and N S Young. Defective stromal
cell function in a mouse model of infusion-induced bone marrow failure. Exp
Hematol, 33(8):901–8, Aug 2005.
[149] S X Hsiong and D J Mooney. Regeneration of vascularized bone. Periodontol
2000, 41:109–22, 2006.
[150] A Islam, D Catovsky, J M Goldman, and D A Galton. Histomorphological
study of cellular interactions between stromal and haemopoietic stem cells in
normal and leukaemic bone marrow. Histopathology, 8(2):293–313, 1984.
[151] M J Kiel, O H Yilmaz, T Iwashita, O H Yilmaz, C Terhorst, and S J Morrison.
Slam family receptors distinguish hematopoietic stem and progenitor cells and
reveal endothelial niches for stem cells. Cell, 121(7):1109–21, 2005.
115
[152] L Kobari, F Pflumio, M Giarratana, X Li, M Titeux, B Izac, F Leteurtre,
L Coulombel, and L Douay. In vitro and in vivo evidence for the long-term
multilineage (myeloid, b, nk, and t) reconstitution capacity of ex vivo expanded
human cd34(+) cord blood cells. Exp Hematol, 28(12):1470–80, 2000.
[153] M Punzel, K A Moore, I R Lemischka, and C M Verfaillie. The type of stromal
feeder used in limiting dilution assays influences frequency and maintenance
assessment of human long-term culture initiating cells. Leukemia, 13(1):92–7,
1999.
[154] Z Tang, N A Kotov, S Magonov, and B Ozturk. Nanostructured artificial nacre.
Nat Mater, 2(6):413–8, 2003.
[155] C I Civin, T Trischmann, N S Kadan, J Davis, S Noga, K Cohen, B Duffy,
I Groenewegen, J Wiley, P Law, A Hardwick, F Oldham, and A Gee. Highly pu-
rified cd34-positive cells reconstitute hematopoiesis. J Clin Oncol, 14(8):2224–
33, 1996.
[156] K G Murti, P S Brown, M a Kumagai, and D Campana. Molecular interactions
between human b-cell progenitors and the bone marrow microenvironment. Exp
Cell Res, 226(1):47–58, 1996.
[157] L M Calvi, G B Adams, K W Weibrecht, J M Weber, D P Olson, M C Knight,
R P Martin, E Schipani, P Divieti, F R Bringhurst, L A Milner, H M Kronen-
berg, and D T Scadden. Osteoblastic cells regulate the haematopoietic stem
cell niche. Nature, 425(6960):841–6, 2003.
[158] F Djouad, B Delorme, M Maurice, C Bony, F Apparailly, P Louis-Plence,
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